🏷

Classifications

Harrison's Part

◆

Subtypes

4

Spastic cerebral palsy MONDO:0000396

Increased muscle tone and spasticity, with unilateral hemiplegic or bilateral diplegic/quadriplegic distributions. This is the most common motor type; severity varies within each topographic category.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Eighty-five percent of children with cerebral palsy have spasticity as their primary motor type"

Supports predominance of the spastic motor type in the population summarized.

Dyskinetic cerebral palsy MONDO:0022697

Involuntary dystonic or athetoid movements, often with deep gray-matter abnormalities. MONDO lists dyskinetic cerebral palsy as an exact synonym of athetoid cerebral palsy; the clinical description includes dystonia as well as athetosis.

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"dyskinesia (4%−7%), including dystonia and athetosis"

The clinical review defines the dyskinetic motor category.

Ataxic cerebral palsy MONDO:0000397

Least common form, characterized by impaired balance and coordination from cerebellar dysfunction.

Mixed cerebral palsy MONDO:0000400

Coexisting motor types, commonly spasticity and dyskinesia. Mixed motor findings need not imply multiple separate acquired lesions.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Many children have a mixed presentation involving both motor types"

Supports coexistence of spasticity and dyskinesia.

?

Discussions and Knowledge Gaps

2

Can hypoxic injury in the xenocortication platform model the persistent motor dysfunction of cerebral palsy?

HUMAN MODEL MISMATCH OPEN xcx_hypoxia_translation_to_cerebral_palsy

Attached to

animal_models#Mouse pathophysiology#Non-Progressive Developing-Brain Disturbance

The paper introduces a human cortical development and circuit platform and demonstrates hypoxic injury as an application. Its cerebral-palsy connection is prospective. The demonstrated cellular responses and short-term mouse gait changes do not establish the persistent human motor syndrome, the full hypoxic-ischemic injury cascade, or a causal chain from HIF1α through gliosis to impaired gait. Immature cortical organization, mixed human and mouse cellular contributions, and unresolved graft-specific behavioural causality constrain translation. Longitudinal motor assessment and graft-specific perturbations would be needed to assess that connection.

Show evidence (3 references)

PMID:42749812 SUPPORT Model organism

"For example, XCX mice display gait deficits following hypoxic injury, highlighting the potential for modelling perinatal hypoxia and associated cerebral palsy49 as well as human neurodevelopmental disorders more broadly."

The authors explicitly frame perinatal hypoxia and associated cerebral palsy as potential applications, supporting inclusion as a prospective connection.

PMID:42749812 SUPPORT Model organism

"The observed behavioural outputs probably reflect interactions between the human graft and preserved mouse subcortical circuits, but whether graft-derived neurons are necessary or sufficient for specific behaviours remains unclear."

The authors leave graft-neuron necessity and sufficiency for behaviour unresolved.

PMID:42749812 SUPPORT Model organism

"At the timepoints examined, the XCX graft lacked several features of mature cortical circuitry, including complete areal patterning, a well-defined laminar cortical plate, full representation of GABAergic interneurons and a mature transcriptional profile."

Documents incomplete areal patterning, lamination, interneuron representation and transcriptional maturity.

How should CTNNB1 causation be represented on the clinical CP umbrella alongside CTNNB1-related neurodevelopmental disorder?

OPEN QUESTION OPEN ctnnb1_clinical_umbrella_relationship

Attached to

genetic#CTNNB1

Primary CP-ascertained evidence supports recurrent damaging CTNNB1 variants, whereas the larger CTNNB1 phenotype comparison does not identify a separate CP subgroup. The unresolved question is how to distinguish causation of the molecular disorder from its representation under a clinical motor-syndrome umbrella. See issue #11823.

Show evidence (2 references)

PMID:32989326 SUPPORT Human clinical

"CTNNB1, encoding β-catenin, harbors three LoF DNMs"

Primary results identify loss-of-function de novo variants in CP-ascertained individuals.

PMID:36083290 SUPPORT Human clinical

"In summary, individuals with P/LP CTNNB1 variants were similarly affected irrespective of their CP diagnosis."

The later phenotype comparison does not support CP as a separate CTNNB1 molecular subgroup.

⚙

Pathophysiology

15

Non-Progressive Developing-Brain Disturbance

The clinical cerebral palsy syndrome reflects a non-progressive disturbance of the developing brain. This encompasses abnormal development as well as acquired injury; a demonstrable fixed lesion or birth asphyxia is not required. Motor function and secondary complications can change during growth.

Downstream

Spasticity Disrupted early brain development can manifest with this motor pattern; it is not present in every CP subtype.

Dystonia Disrupted early brain development can manifest with this motor pattern; it is not present in every CP subtype.

Choreoathetosis Disrupted early brain development can manifest with this motor pattern; it is not present in every CP subtype.

Ataxia Disrupted early brain development can manifest with this motor pattern; it is not present in every CP subtype.

Secondary Musculoskeletal Pathology Contractures and hip displacement develop during growth as complications of the CP motor disorder; the intermediate neuromuscular and biomechanical steps are not resolved here.

Show evidence (2 references)

PMID:32989326 SUPPORT Human clinical

"CP was thus defined as a non-progressive developmental disorder of movement and/or posture impairing motor function."

States the operational non-progressive, movement/posture definition of cerebral palsy.

PMID:30963790 SUPPORT Other

"Cerebral palsy is, and should remain, an umbrella concept and clinical diagnosis that encompasses the diverse motor phenotypes/topographies and etiologies of this disorder"

Consensus discussion supports retaining a clinical umbrella across distinct etiologies; it does not establish a single causal pathway.

Periventricular White Matter Injury

Periventricular leukomalacia includes focal white-matter necrosis and diffuse glial injury in the premature brain. Cystic lesions can interrupt motor pathways and are associated with spastic diplegia; diffuse noncystic injury often has cognitive sequelae without major motor deficits.

periventricular white matter UBERON:0002316

Downstream

Non-Progressive Developing-Brain Disturbance Periventricular injury can leave persistent developmental brain abnormalities; a cerebral palsy diagnosis additionally requires the clinical motor syndrome.

Spastic diplegia Cystic PVL is associated with the spastic diplegic phenotype; this inference does not extend to all noncystic white-matter injury.

Show evidence (2 references)

PMID:19081519 SUPPORT Human clinical

"With regard to PVL, cystic PVL probably accounts for the small group of infants who show spastic diplegia."

The full text ties the spastic diplegic phenotype specifically to cystic PVL.

PMID:19081519 SUPPORT Human clinical

"Non-cystic PVL correlates with the cognitive deficits observed later, usually in the absence of major motor deficits."

Prevents treating all white-matter injury as sufficient for a motor CP diagnosis.

Premyelinating Oligodendrocyte Injury

Vulnerable premyelinating oligodendrocytes in premature white matter undergo cell loss or process injury. This is a cellular component of diffuse PVL, distinct from focal tissue necrosis.

premyelinating oligodendrocyte precursor cell CL:0002453 ↓ DECREASED

Downstream

Oligodendrocyte Maturation Failure Following initial injury, oligodendroglial progenitors may repopulate but fail to mature; the regenerative failure is particularly well documented in experimental PVL.

Show evidence (1 reference)

PMID:19081519 SUPPORT Other

"Injury of pre-OLs consists of cell loss or process loss (with intact soma)."

The review distinguishes loss of precursor cells from loss of their processes; it synthesizes human pathology and experimental mechanisms.

Oligodendrocyte Maturation Failure

Regenerating oligodendroglial progenitors fail to complete differentiation into mature myelin-producing cells after premature white-matter injury. The precise cause of this maturation disturbance remains unresolved.

oligodendrocyte differentiation GO:0048709 ↓ DECREASED

Animal models

Preterm fetal sheep cerebral ischemia Sheep partially recapitulates Progenitor proliferation without maturation after fetal cerebral ischemia models the maturation-failure component of premature white-matter injury.

Downstream

White Matter Hypomyelination An inadequate mature oligodendrocyte population impairs subsequent myelination.

Show evidence (1 reference)

PMID:19081519 SUPPORT Other

"However, in PVL, these cells, which often lack processes, seem not to have the capacity for full differentiation to mature myelin-producing cells, and hypomyelination with ventriculomegaly is the later sequela."

Full-text account of oligodendroglial repopulation without effective maturation and subsequent hypomyelination.

White Matter Hypomyelination

Reduced myelination is a developmental consequence of oligodendroglial injury and maturation failure in diffuse PVL. It is not synonymous with cystic destruction of motor tracts or sufficient by itself to diagnose cerebral palsy.

myelination GO:0042552 ↓ DECREASED

white matter UBERON:0002316

Show evidence (1 reference)

PMID:19081519 SUPPORT Other

"However, in PVL, these cells, which often lack processes, seem not to have the capacity for full differentiation to mature myelin-producing cells, and hypomyelination with ventriculomegaly is the later sequela."

Full-text account of oligodendroglial repopulation without effective maturation and subsequent hypomyelination.

Mitochondrial Energy Production Failure

Mitochondrial energy production is impaired during neonatal hypoxic-ischemic injury.

Show evidence (1 reference)

PMID:32112349 SUPPORT Other

"HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."

Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.

Glutamate Excitotoxicity

Excessive glutamatergic signaling contributes to hypoxic-ischemic cellular injury.

glutamate receptor signaling pathway GO:0007215 ↑ INCREASED

Show evidence (1 reference)

PMID:32112349 SUPPORT Other

"HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."

Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.

Oxidative Cellular Injury

Oxidative stress contributes to cellular injury after neonatal hypoxia-ischemia.

response to oxidative stress GO:0006979 ↑ INCREASED

Show evidence (1 reference)

PMID:32112349 SUPPORT Other

"HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."

Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.

Neuronal Apoptosis

Apoptotic neuronal loss is one component of neonatal hypoxic-ischemic injury.

neuron CL:0000540 ↓ DECREASED

apoptotic process GO:0006915 ↑ INCREASED

Show evidence (1 reference)

PMID:32112349 SUPPORT Other

"HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."

Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.

Hypoxic-Ischemic Encephalopathy

Neonatal hypoxia-ischemia produces encephalopathy and can injure the developing brain. Its cellular injury mechanisms are represented separately; not every affected newborn develops cerebral palsy.

Downstream

Mitochondrial Energy Production Failure The HIE review identifies this cellular process within the injury response; no fixed ordering among these interacting mechanisms is asserted.

Glutamate Excitotoxicity The HIE review identifies this cellular process within the injury response; no fixed ordering among these interacting mechanisms is asserted.

Oxidative Cellular Injury The HIE review identifies this cellular process within the injury response; no fixed ordering among these interacting mechanisms is asserted.

Neuronal Apoptosis The HIE review identifies this cellular process within the injury response; no fixed ordering among these interacting mechanisms is asserted.

Non-Progressive Developing-Brain Disturbance Hypoxic-ischemic injury can leave a persistent developmental disturbance, with CP occurring in a subset of survivors.

Show evidence (1 reference)

PMID:32112349 SUPPORT Other

"HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."

Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.

Perinatal Neuroinflammation

Microglial activation accompanies inflammatory injury in the premature brain. Inflammation and ischemia can potentiate each other; experimental and neuropathological evidence implicates microglial mediators in vulnerable oligodendrocyte injury.

microglial cell CL:0000129 ↑ INCREASED

microglial cell activation GO:0001774 ↑ INCREASED neuroinflammatory response GO:0150076 ↑ INCREASED

Downstream

Premyelinating Oligodendrocyte Injury Microglial free radicals, cytokines and enhanced excitotoxicity contribute to injury of vulnerable pre-OLs in premature white matter.

Show evidence (1 reference)

PMID:19081519 SUPPORT Other

"Microglia seem to be key effectors of cellular injury with both ischaemia and inflammation."

Mechanistic review supports microglia as injury effectors; this is not a causal inference from the chorioamnionitis association alone.

Basal Ganglia and Thalamic Injury

Deep gray-matter injury is an anatomic substrate associated with dyskinetic cerebral palsy. The motor phenotype depends on the affected circuits and accompanying lesions.

basal ganglia UBERON:0002420

Downstream

Dystonia Deep gray-matter lesions can disrupt motor circuitry in dyskinetic CP; the diagnostic review supplies a clinical-imaging association.

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"Gray matter injury (21%) with thalamic and lentiform nuclear injury"

Table 2 associates this MRI pattern with the dyskinesia column; it does not establish the cause of every dyskinetic presentation.

Bilirubin Encephalopathy (Kernicterus)

Bilirubin-induced neurologic injury can produce the classical kernicterus syndrome, including athetoid cerebral palsy, impaired upward gaze and deafness.

basal ganglion UBERON:0002420

Downstream

Choreoathetosis Classical kernicterus includes the athetoid motor phenotype.

Show evidence (2 references)

PMID:15578034 SUPPORT Human clinical

"traditional and evolving definitions ranging from classical kernicterus with athetoid cerebral palsy, impaired upward gaze and deafness"

Defines classical kernicterus (bilirubin encephalopathy) as producing athetoid (dyskinetic) cerebral palsy with impaired upgaze and deafness.

PMID:15578034 SUPPORT Human clinical

"magnetic resonance imaging showing bilateral lesions of globus pallidus+/-subthalamic nucleus."

The review describes deep-nuclear imaging findings in a proposed kernicterus case definition; this does not directly measure bilirubin deposition.

Secondary Musculoskeletal Pathology

Contractures and progressive hip displacement may develop during growth despite a non-progressive underlying brain disturbance. Their course reflects multiple neuromuscular and biomechanical factors; reducing spasticity alone does not establish prevention of deformity.

Downstream

Joint contractures Secondary musculoskeletal change can restrict joint range.

Hip dislocation Progressive displacement can culminate in dislocation; surveillance aims to prevent this outcome.

Show evidence (2 references)

PMID:32086598 SUPPORT Human clinical

"Contracture is a common complication, particularly for children with spastic cerebral palsy."

Supports contracture as an evolving complication.

PMID:32086598 SUPPORT Human clinical

"One in three children in high-income countries experience progressive hip displacement as a complication of their cerebral palsy"

Supports progressive secondary hip pathology in the populations discussed.

Genetically Mediated Neuritogenesis Disturbance

Mechanism confidence: Hypothetical

A subset of CP-associated variants may disturb early neuronal process formation and circuit connectivity. This is a convergent mechanistic hypothesis from genetic and functional studies, not a proven common mechanism in all CP.

neuron projection development GO:0031175 ⚠ ABNORMAL

Downstream

Non-Progressive Developing-Brain Disturbance Abnormal early neuronal connectivity is proposed to contribute to the developmental brain disturbance in genetically mediated CP.

Show evidence (1 reference)

PMID:32989326 SUPPORT Other

"we therefore predict that disruption of genes involved in neurodevelopmental patterning may alter early neuritogenesis and neuronal functional network connectivity in CP."

The primary study integrates genetic, network and experimental evidence, but explicitly frames the neuronal-connectivity mechanism as a prediction.

⬡

Pathograph

Use Group by to collapse related nodes into one box. Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

25

Digestive 1

Dysphagia FREQUENT HP:0002015

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Half of all children with cerebral palsy have dysphagia and the prevalence is even higher in the infant population"

The systematic review reports swallowing impairment as a frequent associated problem.

Ear 1

Hearing impairment HP:0000365

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"1 in 25 were deaf"

Population-based systematic review; ~4% of children with CP are deaf, the severe end of the hearing-impairment spectrum. (Frequency band omitted because the statistic quantifies deafness, a narrower phenotype than the annotated HP term.)

Eye 2

Visual impairment HP:0000505

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"1 in 10 were blind"

Population-based systematic review; ~10% of children with CP are blind, the severe end of the visual-impairment spectrum. (Frequency band omitted because the statistic quantifies blindness, a narrower phenotype than the annotated HP term.)

Strabismus HP:0000486

Genitourinary 1

Bladder control problems OCCASIONAL Functional abnormality of the bladder HP:0000009

Coarse binding: source unspecified

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"1 in 4 had bladder control problems"

The review reports the broad finding in one quarter, without establishing a specific mechanism or urinary subtype.

Head and Neck 1

Drooling OCCASIONAL HP:0002307

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"1 in 5 dribbled; 1 in 10 were blind"

Population-based systematic review; ~20% (1 in 5) of children with CP drool/dribble (sialorrhea), supporting the OCCASIONAL band. (The trailing clause is contiguous list context from the same sentence.)

Limbs 1

Hip dislocation HP:0002827

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"comprehensive multidisciplinary intervention (including botulinum toxin, weight-bearing, motor training, and orthopedic surgery) at the right time and the right dose can prevent hip dislocation"

The treatment review specifically discusses frank dislocation as a preventable complication; the broader displacement statistic is not assigned to this narrower phenotype.

Musculoskeletal 6

Spasticity HP:0001257

Show evidence (1 reference)

PMID:32989326 SUPPORT Human clinical

"Movement disorder (spasticity, dystonia, choreoathetosis and/or ataxia) onset occurs within the first few years of life as a manifestation of disrupted brain development"

Enumerates spasticity as a core CP motor manifestation arising from disrupted brain development.

Spastic diplegia HP:0001264

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"diplegia (lower limbs affected more than upper limbs)"

The early-diagnosis review describes this motor presentation.

Spastic tetraplegia HP:0002510

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"quadriplegia (all 4 limbs and trunk affected)"

The early-diagnosis review describes this motor presentation.

Hypotonia HP:0001252

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"hypotonia (2%), which is not classified in all countries"

The early-diagnosis review describes this motor presentation.

Scoliosis HP:0002650

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"infants with bilateral cerebral palsy who receive regular surveillance and intervention have lower rates of hip displacement, contracture, and scoliosis"

The review identifies scoliosis as a secondary complication in bilateral CP.

Joint contractures HP:0034392

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Contracture is a common complication, particularly for children with spastic cerebral palsy."

Supports contracture as an evolving complication.

Nervous System 11

Hemiplegia HP:0002301

Show evidence (1 reference)

PMID:20497457 SUPPORT Human clinical

"the frequency, risk factors, manifestations, and outcome of epilepsy in children with hemiplegic cerebral palsy (CP) due to perinatal arterial ischaemic stroke (AIS)"

Population-based CP-register study of hemiplegic CP caused by perinatal arterial ischemic stroke.

Dystonia HP:0001332

Show evidence (1 reference)

PMID:32989326 SUPPORT Human clinical

"Movement disorder (spasticity, dystonia, choreoathetosis and/or ataxia) onset occurs within the first few years of life as a manifestation of disrupted brain development"

Lists dystonia among the core CP movement-disorder manifestations.

Choreoathetosis HP:0002305

Show evidence (1 reference)

PMID:32989326 SUPPORT Human clinical

"Movement disorder (spasticity, dystonia, choreoathetosis and/or ataxia) onset occurs within the first few years of life as a manifestation of disrupted brain development"

Lists choreoathetosis among the core CP movement-disorder manifestations.

Ataxia HP:0001251

Show evidence (1 reference)

PMID:32989326 SUPPORT Human clinical

"Movement disorder (spasticity, dystonia, choreoathetosis and/or ataxia) onset occurs within the first few years of life as a manifestation of disrupted brain development"

Lists ataxia among the core CP movement-disorder manifestations.

Delayed gross motor development HP:0002194

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"parents, caregivers, or community-based professionals first notice delayed motor milestones"

Delayed milestones are a presenting diagnostic signal.

Gait disturbance HP:0001288

Intellectual disability FREQUENT HP:0001249

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"1 in 2 had an intellectual disability"

Population-based systematic review quantifying intellectual disability in ~50% of children with CP (FREQUENT band).

Seizures OCCASIONAL HP:0001250

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"1 in 4 had epilepsy"

Population-based systematic review quantifying epilepsy in ~25% of children with CP (OCCASIONAL band).

Absent speech OCCASIONAL HP:0001344

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"1 in 4 could not talk"

The review reports inability to talk in approximately one quarter; it does not establish dysarthria or anarthria as the cause.

Behavioral abnormality OCCASIONAL Atypical behavior HP:0000708

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"1 in 4 had a behavior disorder"

Population-based systematic review quantifying a behavior disorder in ~25% of children with CP (OCCASIONAL band).

Sleep disturbance OCCASIONAL HP:0002360

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"1 in 5 had a sleep disorder"

Population-based systematic review quantifying a sleep disorder in ~20% of children with CP (OCCASIONAL band).

Constitutional 1

Chronic pain FREQUENT HP:0012531

Show evidence (1 reference)

PMID:23045562 SUPPORT Human clinical

"3 in 4 were in pain"

Population-based systematic review quantifying pain in ~75% of children with CP — the most common comorbidity (FREQUENT band).

🧬

Genetic Associations

3

Monogenic and de novo genetic contributions

relationship_type: SUSCEPTIBILITY

Show evidence (3 references)

PMID:32989326 SUPPORT Human clinical

"We found an enrichment of damaging DNMs in CP cases, which became more apparent when focusing the analysis on genes intolerant to LoF variation"

Whole-exome sequencing of 250 CP trios shows enrichment of damaging de novo mutations, implicating monogenic genetic contributions (e.g., CTNNB1, TUBA1A).

PMID:30564460 SUPPORT Human clinical

"Combined SNV and CNV analysis revealed pathogenic and likely pathogenic variants in 22.7% of unselected individuals with CP."

Combined prior sequence-variant analyses with the CNV analysis of an unselected Australian CP cohort. The full text reports seven additional cases among 186 analyzed (3.7%) and a combined yield of 22.7%; this is not a universal CP prevalence estimate.

PMID:38553553 SUPPORT Human clinical

"Multiple classes of P/LP variants included single-nucleotide variants (SNVs)/indels (6.7%), copy number variations (3.4%) and mitochondrial mutations (1.5%)."

The whole-genome cohort illustrates variant-class diversity; these are cohort-specific yields and categories need not be mutually exclusive.

CTNNB1

Gene: CTNNB1 hgnc:2514 gene page relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (2 references)

PMID:32989326 SUPPORT Human clinical

"CTNNB1, encoding β-catenin, harbors three LoF DNMs"

Primary results identify loss-of-function de novo variants in CP-ascertained individuals.

PMID:36083290 SUPPORT Human clinical

"In summary, individuals with P/LP CTNNB1 variants were similarly affected irrespective of their CP diagnosis."

The later phenotype comparison does not support CP as a separate CTNNB1 molecular subgroup.

TUBA1A

Gene: TUBA1A hgnc:20766 gene page relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (1 reference)

PMID:32989326 SUPPORT Human clinical

"of these, two (TUBA1AandCTNNB1) met genome-wide significance."

Recurrent damaging de novo mutations in TUBA1A (and CTNNB1) reached genome-wide significance in CP trios.

💊

Medical Actions

14

Physical therapy

Action: physical therapy Ontology label: Physical Therapy NCIT:C15302

Platform: Behavioral / lifestyle

Active, goal-directed practice of meaningful motor tasks, with strength or mobility training selected for the specific functional goal. Improvements in strength or tone should not be assumed to generalize automatically to activity or participation.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"practice of real-life tasks and activities, using self-generated active movements, at a high intensity"

The full text identifies active practice as a shared feature of effective motor interventions.

Occupational therapy

Action: occupational therapy Ontology label: Occupational Therapy NCIT:C121351

Platform: Behavioral / lifestyle

Goal-directed practice of daily activities and hand use. Constraint-induced movement therapy and bimanual training are evidence-supported approaches, particularly for unilateral motor impairment; goals and tasks are individualized.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Substantive clinical trial data support the efficacy of training-based interventions"

The review details bimanual, constraint-induced, goal-directed and other active training approaches.

Speech and language therapy

Action: speech and language therapy Ontology label: Speech Language Therapy NCIT:C159273

Platform: Behavioral / lifestyle

Individualized communication support, including augmentative and alternative communication when speech is inadequate; feeding and swallowing difficulties require specific assessment.

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"provide compensation when speech is not possible or is inadequate"

The early-intervention recommendations support communication alternatives.

Botulinum toxin injection

Action: Pharmacotherapy NCIT:C15986

Agent: botulinum toxin type A CHEBI:3160

Platform: Other

Intramuscular botulinum toxin type A for focal spasticity and dystonia.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Effective medical and surgical interventions include anti-convulsants, bisphosphonates, botulinum toxin, botulinum toxin plus occupational therapy, botulinum toxin plus casting, diazepam, dentistry, hip surveillance, intrathecal baclofen, scoliosis correction, selective dorsal rhizotomy, and..."

Systematic-review traffic-light appraisal listing botulinum toxin among effective CP interventions.

Intrathecal baclofen

Action: Pharmacotherapy NCIT:C15986

Agent: baclofen CHEBI:2972

Platform: Small molecule

Intrathecal baclofen can reduce spasticity. The cited systematic-review evidence is route-specific and does not establish efficacy of oral baclofen or functional gains from tone reduction alone.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Effective medical and surgical interventions include anti-convulsants, bisphosphonates, botulinum toxin, botulinum toxin plus occupational therapy, botulinum toxin plus casting, diazepam, dentistry, hip surveillance, intrathecal baclofen, scoliosis correction, selective dorsal rhizotomy, and..."

Systematic-review traffic-light appraisal listing intrathecal baclofen among effective CP interventions.

Selective dorsal rhizotomy

Action: Surgical Procedure NCIT:C15329

Platform: Surgery

Neurosurgical sectioning of selected dorsal (sensory) nerve rootlets to reduce lower-limb spasticity in carefully selected ambulant children with spastic diplegia.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Effective medical and surgical interventions include anti-convulsants, bisphosphonates, botulinum toxin, botulinum toxin plus occupational therapy, botulinum toxin plus casting, diazepam, dentistry, hip surveillance, intrathecal baclofen, scoliosis correction, selective dorsal rhizotomy, and..."

Systematic-review traffic-light appraisal listing selective dorsal rhizotomy among effective CP interventions.

Orthopedic surgery

Action: Surgical Procedure NCIT:C15329

Platform: Surgery

Muscle-tendon lengthening, hip reconstruction, and scoliosis correction for established musculoskeletal deformities.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Once a contracture is severe (e.g., greater than 20°) and longstanding, casting will no longer be sufficient in isolation, and orthopedic surgery requires consideration."

The review discusses surgery for established contracture with individualized timing and functional assessment.

Supportive and multidisciplinary care

Action: Supportive Care NCIT:C15747

Platform: Other

Coordinated management including orthoses, assistive devices, nutrition, management of epilepsy, pain, and orthopedic surveillance (e.g., hip surveillance programs).

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"prevent secondary impairments and minimize the influence of complications that worsen function or interfere with learning"

The review recommends care addressing associated impairments and secondary complications.

Antenatal magnesium sulfate (fetal neuroprotection)

Action: Pharmacotherapy NCIT:C15986

Agent: magnesium sulfate CHEBI:32599

Platform: Small molecule

Magnesium sulfate given to women at risk of imminent preterm birth reduces the risk of cerebral palsy in the offspring. This is an established antenatal neuroprotective (preventive) intervention, not a treatment of established CP.

Show evidence (3 references)

PMID:39724363 SUPPORT Human clinical

"Our meta-analysis including eight RCTs showed that magnesium sulfate reduced the risk of cerebral palsy without a significant change in pediatric mortality."

Meta-analysis of RCTs showing antenatal magnesium sulfate reduces CP risk in preterm-labor pregnancies.

PMID:32086598 SUPPORT Human clinical

"Effective prevention strategies include antenatal corticosteroids, magnesium sulfate, caffeine, and neonatal hypothermia."

Systematic review listing antenatal magnesium sulfate among effective CP prevention strategies.

PMID:39724363 SUPPORT Human clinical

"The effect of antenatal administration of MgSO4 showed no significant effect on the composite primary outcome of pediatric mortality and CP."

The full-text discussion distinguishes the CP outcome from the composite endpoint.

Therapeutic hypothermia (neonatal neuroprotection)

Action: Therapeutic Procedure NCIT:C49236

Platform: Other

Whole-body or selective head cooling initiated within 6 hours of birth in term/late-preterm newborns with moderate-to-severe hypoxic-ischemic encephalopathy reduces death and long-term neurodevelopmental disability, including cerebral palsy. This is a preventive neuroprotective intervention applied in the neonatal period, not a treatment of established CP.

Show evidence (1 reference)

PMID:23440789 SUPPORT Human clinical

"There is evidence from the 11 randomised controlled trials included in this systematic review (N = 1505 infants) that therapeutic hypothermia is beneficial in term and late preterm newborns with hypoxic ischaemic encephalopathy."

Cochrane meta-analysis showing cooling reduces death and neurodevelopmental disability after neonatal HIE, a major cause of CP.

Hip surveillance

Platform: Other

Structured surveillance with timely multidisciplinary assessment and intervention aims to detect displacement early and prevent dislocation. Surveillance benefit should not be attributed to any single tone-reducing treatment.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"There is moderate-quality evidence and a strong recommendation to use comprehensive hip surveillance practices to facilitate early detection and management of hip displacement"

The review supports comprehensive surveillance and response to findings.

Antenatal corticosteroids

Action: Pharmacotherapy NCIT:C15986

Agent: corticosteroid CHEBI:50858

Platform: Small molecule

Antenatal corticosteroids in the preterm-birth setting reduce intracranial hemorrhage and provide fetal neuroprotection. This is prevention in a selected obstetric population, not treatment of established CP.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Antenatal corticosteroids decrease intracranial hemorrhage and thereby also act as an effective neuroprotectant"

The full systematic review supports this intervention within the specified clinical context.

Neonatal caffeine

Action: Pharmacotherapy NCIT:C15986

Agent: caffeine CHEBI:27732

Platform: Small molecule

Caffeine in selected mechanically ventilated premature infants is a neonatal preventive strategy. This evidence does not support caffeine as a treatment for established CP.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Once an infant is born preterm and is mechanically ventilated, prophylactic caffeine (methylxanthines) prior to extubation effectively prevents cerebral palsy"

The full systematic review supports this intervention within the specified clinical context.

Diazepam for spasticity

Action: Pharmacotherapy NCIT:C15986

Agent: diazepam CHEBI:49575

Platform: Small molecule

Diazepam can reduce spasticity. Treatment goals and tolerability require individualized assessment; reduced tone does not itself establish improved mobility.

Show evidence (1 reference)

PMID:32086598 SUPPORT Human clinical

"Effective medical and surgical interventions include anti-convulsants, bisphosphonates, botulinum toxin, botulinum toxin plus occupational therapy, botulinum toxin plus casting, diazepam, dentistry, hip surveillance, intrathecal baclofen, scoliosis correction, selective dorsal rhizotomy, and..."

The systematic review lists diazepam among the medical interventions it graded as effective.

🌍

Environmental Factors

6

Preterm birth and low birth weight

CP risk rises with decreasing gestational age and birth weight. Premature white matter is developmentally vulnerable to injury.

Show evidence (2 references)

PMID:23346889 SUPPORT Human clinical

"The prevalence of CP expressed by gestational age was highest in children born before 28 weeks' gestation (111.80 per 1000 live births; 95% CI 69.53-179.78; p<0.0327)."

Supports the high CP prevalence in children born before 28 weeks; this association does not itself prove a specific cellular mechanism.

PMID:19081519 SUPPORT Human clinical

"Brain injury in premature infants is of enormous public health importance because of the large number of such infants who survive with serious neurodevelopmental disability, including major cognitive deficits and motor disability."

Links premature brain injury to the motor disability that manifests as cerebral palsy.

Mechanism Target:

PREDISPOSES Periventricular White Matter Injury — Developmental vulnerability of premature white matter predisposes to injury; prematurity does not invariably trigger a lesion.

Show evidence (1 reference)

PMID:19081519 SUPPORT Other

"Various maturation-dependent factors, including a propensity for premature infants to experience episodes of cerebral ischaemia and infection or inflammation, and an intrinsic susceptibility to excitotoxicity and free-radical accumulation, converge to accentuate vulnerability."

Mechanistic review supports developmental susceptibility in premature white matter.

Perinatal asphyxia / hypoxic-ischemic insult

A hypoxic-ischemic insult around birth can cause neonatal encephalopathy, one recognized etiologic pathway to CP.

Show evidence (1 reference)

PMID:32112349 SUPPORT Human clinical

"Hypoxic-ischemic encephalopathy, also referred as HIE, is a type of brain injury or damage that is caused by a lack of oxygen to the brain during neonatal period."

States that the injury is caused by a lack of oxygen to the brain during the neonatal period, which is the causal claim this link makes rather than merely a definition of the entity.

Mechanism Target:

TRIGGERS Hypoxic-Ischemic Encephalopathy — Inadequate oxygen delivery during the neonatal period can cause hypoxic-ischemic brain injury.

Show evidence (1 reference)

PMID:32112349 SUPPORT Human clinical

"Hypoxic-ischemic encephalopathy, also referred as HIE, is a type of brain injury or damage that is caused by a lack of oxygen to the brain during neonatal period."

States that the injury is caused by a lack of oxygen to the brain during the neonatal period, which is the causal claim this link makes rather than merely a definition of the entity.

Intrauterine infection and inflammation

Chorioamnionitis is associated with increased CP risk. This epidemiologic association is distinct from the mechanistic evidence concerning inflammatory brain injury.

Show evidence (1 reference)

PMID:10989405 SUPPORT Human clinical

"Among full-term infants, a positive association was found between clinical chorioamnionitis and cerebral palsy (RR, 4.7; 95% CI, 1.3-16.2)."

Meta-analysis quantifying the association between chorioamnionitis and CP in full-term infants.

Mechanism Target:

TRIGGERS Perinatal Neuroinflammation — Maternal intrauterine infection can initiate inflammation relevant to premature brain injury.

Show evidence (1 reference)

PMID:19081519 SUPPORT Other

"The main initiating pathogenetic mechanisms are ischaemia and inflammation, the latter often due to maternal intrauterine infection or postnatal sepsis."

Review of premature brain injury supports inflammation after maternal intrauterine infection as an initiating route.

Perinatal stroke

Perinatal arterial ischemic stroke is a recognized cause of unilateral cerebral palsy.

Show evidence (1 reference)

PMID:20497457 SUPPORT Human clinical

"children with hemiplegic cerebral palsy (CP) due to perinatal arterial ischaemic stroke (AIS)"

Links perinatal arterial ischemic stroke to hemiplegic cerebral palsy.

Mechanism Target:

TRIGGERS Non-Progressive Developing-Brain Disturbance — Perinatal arterial ischemic stroke can leave a persistent focal lesion and unilateral motor impairment.

Show evidence (1 reference)

PMID:20497457 SUPPORT Human clinical

"children with hemiplegic cerebral palsy (CP) due to perinatal arterial ischaemic stroke (AIS)"

Describes hemiplegic cerebral palsy arising from perinatal arterial ischaemic stroke, a focal fixed lesion.

Neonatal hyperbilirubinemia (kernicterus)

Neonatal bilirubin toxicity is a recognized cause of the classical kernicterus syndrome, which includes athetoid cerebral palsy.

Show evidence (1 reference)

PMID:15578034 SUPPORT Human clinical

"classical kernicterus with athetoid cerebral palsy, impaired upward gaze and deafness"

Identifies severe neonatal hyperbilirubinemia (kernicterus) as a cause of athetoid cerebral palsy.

Mechanism Target:

TRIGGERS Bilirubin Encephalopathy (Kernicterus) — Severe neonatal bilirubin toxicity can produce the kernicterus syndrome, including athetoid cerebral palsy.

Show evidence (1 reference)

PMID:15578034 SUPPORT Human clinical

"classical kernicterus with athetoid cerebral palsy, impaired upward gaze and deafness"

Describes classical kernicterus with athetoid cerebral palsy, impaired upward gaze and deafness, the clinical syndrome this node represents.

Multiple gestation and intrauterine growth restriction

Twin/multiple pregnancies and fetal growth restriction carry elevated risk.

Show evidence (2 references)

PMID:21860286 SUPPORT Human clinical

"Preterm birth, intrauterine growth restriction, perinatal infection, and multiple birth present the largest risks for a cerebral palsy outcome."

Places both halves of this entry, intrauterine growth restriction and multiple birth, among the largest risks for cerebral palsy, alongside the preterm birth and perinatal infection exposures curated separately here.

PMID:26003063 SUPPORT Human clinical

"Increased risk is associated with preterm delivery, congenital malformations, intrauterine infection, fetal growth restriction, multiple pregnancy, and placental abnormalities."

Independent review listing fetal growth restriction and multiple pregnancy among the exposures that raise cerebral palsy risk.

🔬

Diagnosis

3

Clinical assessment with age-appropriate standardized tools

Diagnosis integrates the movement and posture phenotype, developmental history, neurological examination and exclusion of a progressive disorder. Before five months corrected age, General Movements Assessment, HINE and MRI are complementary tools. A high-risk designation can support early intervention while diagnostic certainty develops.

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"a combination of assessments with strong predictive validity coupled with clinical reasoning is recommended."

Supports combined assessment rather than a single diagnostic test.

Brain MRI

MRI helps identify white-matter injury, deep gray-matter lesions, stroke or maldevelopment. Normal neuroimaging does not exclude clinical CP.

brain magnetic resonance imaging NCIT:C16809

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"approximately 10% have normal neuroimaging"

A normal scan cannot rule out the clinical syndrome.

Etiologic genomic assessment

Genomic testing can identify a molecular etiology and refine counseling. A pathogenic result and a clinical CP diagnosis can coexist when the phenotype meets CP criteria; progressive disorders require diagnostic reconsideration. Variants of uncertain significance do not establish an etiology.

etiologic genomic testing NCIT:C15709

Show evidence (1 reference)

PMID:38553553 SUPPORT Human clinical

"We classified 37 of 327 (11.3%) children as having pathogenic/likely pathogenic (P/LP) variants"

The 327-trio whole-genome study supports a genetic diagnostic yield in a subset, not a universal genetic cause.

📈

Progression

2

Evolving motor phenotype

The underlying disturbance is non-progressive, but motor type and functional severity can change during early development. Early severity predictions require caution.

Show evidence (1 reference)

PMID:28715518 SUPPORT Human clinical

"The motor types and topography of cerebral palsy may emerge and change during the first 2 years of life."

Distinguishes evolution of the clinical phenotype from progressive neurodegeneration.

Secondary musculoskeletal complications

Contractures and hip displacement may progress during growth and require ongoing surveillance and individualized management.

Show evidence (2 references)

PMID:32086598 SUPPORT Human clinical

"Contracture is a common complication, particularly for children with spastic cerebral palsy."

Supports contracture as an evolving complication.

PMID:32086598 SUPPORT Human clinical

"One in three children in high-income countries experience progressive hip displacement as a complication of their cerebral palsy"

Supports progressive secondary hip pathology in the populations discussed.

📊

Prevalence

2

Populations represented in the 2013 systematic review

Prevalence at birth 211.0 per 100,000 (198.0–225.0) >1 in 1,000 (births)

Historical pooled birth prevalence of 2.11 per 1000 live births (95% CI 1.98-2.25) across 49 population-based studies. This estimate is not a current universal rate; prevalence varies by birth cohort and setting.

Show evidence (1 reference)

PMID:23346889 SUPPORT Human clinical

"The pooled overall prevalence of CP was 2.11 per 1000 live births"

Meta-analysis of 49 population-based studies quantifying overall CP prevalence.

Very preterm (born before 28 weeks' gestation)

Prevalence at birth 11180.0 per 100,000 (6953.0–17978.0) >1 in 1,000 (births)

Prevalence rises steeply with decreasing gestational age, reaching 111.80 per 1000 live births in children born before 28 weeks (95% CI 69.53-179.78).

Show evidence (1 reference)

PMID:23346889 SUPPORT Human clinical

"The prevalence of CP expressed by gestational age was highest in children born before 28 weeks' gestation (111.80 per 1000 live births; 95% CI 69.53-179.78; p<0.0327)."

Demonstrates the steep inverse relationship between gestational age and CP prevalence.

🔬

Clinical Trials

4

NCT06586437 NOT_APPLICABLE ACTIVE_NOT_RECRUITING

Cortical and spinal neuromodulation

Show evidence (1 reference)

clinicaltrials:NCT06586437 SUPPORT Human clinical

"Specific Aim 2: To investigate the effect of transcutaneous current stimulation applied over the cortex and/or spinal cord on the sensorimotor cortical activity, spinal cord dynamics, and corticospinal coherence."

The registry summary states the planned intervention or comparison.

NCT05158218 NOT_APPLICABLE ACTIVE_NOT_RECRUITING

Robotic exoskeleton versus conventional gait training

Show evidence (1 reference)

clinicaltrials:NCT05158218 SUPPORT Human clinical

"the participants with CP will undergo the therapeutic gait training using either traditional physical therapy or utilizing a robotic exoskeleton."

The registry summary states the planned intervention or comparison.

NCT04360395 NOT_APPLICABLE ACTIVE_NOT_RECRUITING

Gait training with neuroimaging and neurophysiological outcome assessment

Show evidence (1 reference)

clinicaltrials:NCT04360395 SUPPORT Human clinical

"After completing all of the therapeutic gait training sessions, the participants with CP will repeat the same assessments that were completed at baseline."

The registry summary states the planned intervention or comparison.

NCT04314687 ACTIVE_NOT_RECRUITING

Umbilical-cord mesenchymal stromal cells with or without conditioned medium

Show evidence (1 reference)

clinicaltrials:NCT04314687 SUPPORT Human clinical

"The aim of this study was to compare the effectiveness of umbilical cord mesenchymal stem cells (UCMSCs) and conditioned medium (CM) administration, UCMSCs only and control with standard therapy."

The registry summary states the planned intervention or comparison.

🐁

Animal Models

2

Developmental xenocortication with human cortical organoids (XCX)

Platform for studying developing human cortical cells, circuit integration and host behaviour in vivo. Conditional Esco2 deletion in the Emx1 lineage depletes mouse neocortical and hippocampal glutamatergic neurons, creating space for human stem-cell-derived cortical organoids. The grafts grow extensively, generate diverse cortical cell types and exhibit organized activity. Hypoxic injury to the developing human graft is a proof-of-concept application. The authors identify perinatal hypoxia and associated cerebral palsy as potential future modelling applications; this record does not establish XCX mice as a validated model of cerebral palsy.

Species

Mouse

Genotype

Emx1-cre+/−; Esco2fl/fl; Prkdcscid/scid

Background

Immunodeficient SCID host with neonatal human cortical organoid engraftment.

Publication

PMID:42749812

Notes

Figure 5 uses 5% O2 for 5 hours, preceded by a 1-hour graded descent, as specified by the figure legend and Methods. HIF1α was assessed immediately after exposure and SWI at 10 days; each finding was reported in three XCX mice. Glial measurements at 20 days compared four normoxic and four hypoxia-exposed XCX mice. GFAP-positive astroglia were human graft-derived; IBA1-positive microglia were mouse host-derived. CatWalk measurements compared each animal at baseline and two days after injury: 11 control, nine apallial and nine XCX mice. The apallial hypoxia group contained only females, preventing a complete sex-by-genotype analysis. Reported gait changes were not accompanied by detected group differences in running-speed or step-cadence changes; this is not an equivalence result. Esco2 deletion is host engineering, not evidence for an ESCO2 cause of cerebral palsy. Mechanism links are deliberately unassigned: the existing hypoxic-ischemic encephalopathy node includes mechanisms not established by this hypoxia experiment, and the perinatal neuroinflammation node describes a different initiating context. Acute behavioural readouts do not establish a permanent motor disorder. Graft-neuron necessity or sufficiency for specific behaviours remains unresolved. These model observations are not added as human phenotypes.

Show evidence (17 references)

PMID:42749812 SUPPORT Model organism

"Here we establish a transplantation platform using a genetic strategy to effectively deplete glutamatergic neurons from mouse neocortex and hippocampus (apallial) and neonatally engraft the cortical cavity with human stem-cell-derived cortical organoids (hCO) to generate xenocortical mice."

Establishes the platform design and the human graft in an apallial mouse host.

PMID:42749812 SUPPORT Model organism

"This leads to robust graft growth with hCOs occupying most of the cortical volume and generating a diversity of human cortical cell types, including layer 5 extratelencephalic projection neurons."

Supports graft expansion and cortical cell-type diversity as platform characteristics.

PMID:42749812 SUPPORT Model organism

"Human cortical neurons integrate with the mouse nervous system, and in vivo cortical graft-wide calcium imaging and electrophysiological analyses revealed patterns of organized activity resembling developing circuits."

Reports organized graft activity and integration; it does not demonstrate that graft neurons cause particular host behaviours.

+ 14 more references

Preterm fetal sheep cerebral ischemia

Mid-gestation fetal sheep cerebral ischemia models premature white-matter injury and subsequent oligodendrocyte maturation failure.

Species

Sheep

Publication

PMID:30149778

Pathograph links

Oligodendrocyte Maturation Failure partially recapitulates fidelity: moderate observes: cellular Progenitor proliferation without maturation after fetal cerebral ischemia models the maturation-failure component of premature white-matter injury.

Limitations: Developmental stage and ischemic severity constrain extrapolation to human CP; the model does not reproduce the full clinical syndrome.

Show evidence (1 reference)

PMID:30149778 SUPPORT Model organism

"late progenitors proliferate but fail to mature into myelin producing oligodendrocytes after cerebral ischemia."

The full-text fetal-sheep section reports maturation failure after ischemia.

Developmental stage and insult severity determine injury distribution. This model informs a proximal injury mechanism rather than reproducing the heterogeneous clinical CP syndrome. Intrauterine recovery differs from the human neonatal transition.

{ }

Source YAML

click to show

name: Cerebral Palsy
creation_date: "2026-07-31T00:00:00Z"
synonyms:
- infantile cerebral palsy
category: Complex
disease_term:
  preferred_term: cerebral palsy
  term:
    id: MONDO:0006497
    label: cerebral palsy
parents:
- Neurodevelopmental Disorder
- Movement Disorder
references:
- reference: PMID:42749812
  title: Developmental xenocortication using human-derived organoids in mice.
- reference: PMID:17370477
  title: "A report: the definition and classification of cerebral palsy April 2006."
- reference: PMID:23346889
  title: "An update on the prevalence of cerebral palsy: a systematic review and meta-analysis."
- reference: PMID:32989326
  title: "Mutations disrupting neuritogenesis genes confer risk for cerebral palsy."
- reference: PMID:32086598
  title: "State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy."
- reference: PMID:28715518
  title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
- reference: PMID:30963790
  title: Genetic or Other Causation Should Not Change the Clinical Diagnosis of Cerebral Palsy.
- reference: PMID:38553553
  title: Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy.
- reference: PMID:30149778
  title: 'Perinatal hypoxic-ischemic brain injury in large animal models: Relevance to human neonatal encephalopathy.'
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
prevalence:
- population: Populations represented in the 2013 systematic review
  measure_type: BIRTH_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 211.0
  rate_low: 198.0
  rate_high: 225.0
  notes: >-
    Historical pooled birth prevalence of 2.11 per 1000 live births (95% CI 1.98-2.25) across 49 population-based
    studies. This estimate is not a current universal rate; prevalence varies by birth cohort and setting.
  evidence:
  - reference: PMID:23346889
    reference_title: "An update on the prevalence of cerebral palsy: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pooled overall prevalence of CP was 2.11 per 1000 live births"
    explanation: Meta-analysis of 49 population-based studies quantifying overall CP prevalence.
- population: Very preterm (born before 28 weeks' gestation)
  measure_type: BIRTH_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 11180.0
  rate_low: 6953.0
  rate_high: 17978.0
  notes: >-
    Prevalence rises steeply with decreasing gestational age, reaching 111.80
    per 1000 live births in children born before 28 weeks (95% CI 69.53-179.78).
  evidence:
  - reference: PMID:23346889
    reference_title: "An update on the prevalence of cerebral palsy: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of CP expressed by gestational age was highest in children born before 28 weeks' gestation (111.80 per 1000 live births; 95% CI 69.53-179.78; p<0.0327)."
    explanation: Demonstrates the steep inverse relationship between gestational age and CP prevalence.
has_subtypes:
- name: Spastic
  display_name: Spastic cerebral palsy
  subtype_term:
    preferred_term: spastic cerebral palsy
    term:
      id: MONDO:0000396
      label: spastic cerebral palsy
  description: >-
    Increased muscle tone and spasticity, with unilateral hemiplegic or bilateral diplegic/quadriplegic distributions.
    This is the most common motor type; severity varies within each topographic category.
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eighty-five percent of children with cerebral palsy have spasticity as their primary motor type
    explanation: >-
      Supports predominance of the spastic motor type in the population summarized.
- name: Dyskinetic
  display_name: Dyskinetic cerebral palsy
  subtype_term:
    preferred_term: dyskinetic cerebral palsy
    term:
      id: MONDO:0022697
      label: athetoid cerebral palsy
  description: >-
    Involuntary dystonic or athetoid movements, often with deep gray-matter abnormalities. MONDO lists dyskinetic
    cerebral palsy as an exact synonym of athetoid cerebral palsy; the clinical description includes dystonia as
    well as athetosis.
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      dyskinesia (4%−7%), including dystonia and athetosis
    explanation: >-
      The clinical review defines the dyskinetic motor category.
- name: Ataxic
  display_name: Ataxic cerebral palsy
  subtype_term:
    preferred_term: ataxic cerebral palsy
    term:
      id: MONDO:0000397
      label: ataxic cerebral palsy
  description: >-
    Least common form, characterized by impaired balance and coordination from
    cerebellar dysfunction.
- name: Mixed
  display_name: Mixed cerebral palsy
  subtype_term:
    preferred_term: mixed cerebral palsy
    term:
      id: MONDO:0000400
      label: mixed cerebral palsy
  description: >-
    Coexisting motor types, commonly spasticity and dyskinesia. Mixed motor findings need not imply multiple separate
    acquired lesions.
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Many children have a mixed presentation involving both motor types
    explanation: >-
      Supports coexistence of spasticity and dyskinesia.
pathophysiology:
- name: Non-Progressive Developing-Brain Disturbance
  description: >-
    The clinical cerebral palsy syndrome reflects a non-progressive disturbance of the developing brain. This encompasses
    abnormal development as well as acquired injury; a demonstrable fixed lesion or birth asphyxia is not required.
    Motor function and secondary complications can change during growth.
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:32989326
    reference_title: "Mutations disrupting neuritogenesis genes confer risk for cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CP was thus defined as a non-progressive developmental disorder of movement and/or posture impairing motor function."
    explanation: States the operational non-progressive, movement/posture definition of cerebral palsy.
  - reference: PMID:30963790
    reference_title: Genetic or Other Causation Should Not Change the Clinical Diagnosis of Cerebral Palsy.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Cerebral palsy is, and should remain, an umbrella concept and clinical diagnosis that encompasses the diverse
      motor phenotypes/topographies and etiologies of this disorder
    explanation: >-
      Consensus discussion supports retaining a clinical umbrella across distinct etiologies; it does not establish
      a single causal pathway.
  downstream:
  - target: Spasticity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Disrupted early brain development can manifest with this motor pattern; it is not present in every CP subtype.
    evidence:
    - &id001
      reference: PMID:32989326
      reference_title: Mutations disrupting neuritogenesis genes confer risk for cerebral palsy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Movement disorder (spasticity, dystonia, choreoathetosis and/or ataxia) onset occurs within the first few
        years of life as a manifestation of disrupted brain development
      explanation: >-
        Connects early motor manifestations to disrupted brain development, with different motor patterns in different
        individuals.
  - target: Dystonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Disrupted early brain development can manifest with this motor pattern; it is not present in every CP subtype.
    evidence:
    - *id001
  - target: Choreoathetosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Disrupted early brain development can manifest with this motor pattern; it is not present in every CP subtype.
    evidence:
    - *id001
  - target: Ataxia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Disrupted early brain development can manifest with this motor pattern; it is not present in every CP subtype.
    evidence:
    - *id001
  - target: Secondary Musculoskeletal Pathology
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Contractures and hip displacement develop during growth as complications of the CP motor disorder; the
      intermediate neuromuscular and biomechanical steps are not resolved here.
    evidence:
    - reference: PMID:32086598
      reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Contracture is a common complication, particularly for children with spastic cerebral palsy.
      explanation: >-
        Places contracture as a complication of cerebral palsy, most often of the spastic motor type.
- name: Periventricular White Matter Injury
  description: >-
    Periventricular leukomalacia includes focal white-matter necrosis and diffuse glial injury in the premature
    brain. Cystic lesions can interrupt motor pathways and are associated with spastic diplegia; diffuse noncystic
    injury often has cognitive sequelae without major motor deficits.
  biological_scale: TISSUE
  locations:
  - preferred_term: periventricular white matter
    term:
      id: UBERON:0002316
      label: white matter
  downstream:
  - target: Non-Progressive Developing-Brain Disturbance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Periventricular injury can leave persistent developmental brain abnormalities; a cerebral palsy diagnosis
      additionally requires the clinical motor syndrome.
    evidence:
    - &id002
      reference: PMID:19081519
      reference_title: 'Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        With regard to PVL, cystic PVL probably accounts for the small group of infants who show spastic diplegia.
      explanation: >-
        The full text ties the spastic diplegic phenotype specifically to cystic PVL.
  - target: Spastic diplegia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Cystic PVL is associated with the spastic diplegic phenotype; this inference does not extend to all noncystic
      white-matter injury.
    evidence:
    - *id002
  evidence:
  - *id002
  - reference: PMID:19081519
    reference_title: 'Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non-cystic PVL correlates with the cognitive deficits observed later, usually in the absence of major motor
      deficits.
    explanation: >-
      Prevents treating all white-matter injury as sufficient for a motor CP diagnosis.
- name: Premyelinating Oligodendrocyte Injury
  description: >-
    Vulnerable premyelinating oligodendrocytes in premature white matter undergo cell loss or process injury. This
    is a cellular component of diffuse PVL, distinct from focal tissue necrosis.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: premyelinating oligodendrocyte precursor cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
    modifier: DECREASED
  notes: >-
    Premyelinating oligodendrocytes are bound to the broader CL:0002453 oligodendrocyte precursor cell because no
    pre-oligodendrocyte term is present in cache/cl/terms.csv; preferred_term keeps the developmental stage.
  downstream:
  - target: Oligodendrocyte Maturation Failure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Following initial injury, oligodendroglial progenitors may repopulate but fail to mature; the regenerative
      failure is particularly well documented in experimental PVL.
    evidence:
    - &id003
      reference: PMID:19081519
      reference_title: 'Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        However, in PVL, these cells, which often lack processes, seem not to have the capacity for full differentiation
        to mature myelin-producing cells, and hypomyelination with ventriculomegaly is the later sequela.
      explanation: >-
        Full-text account of oligodendroglial repopulation without effective maturation and subsequent hypomyelination.
  evidence:
  - reference: PMID:19081519
    reference_title: 'Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Injury of pre-OLs consists of cell loss or process loss (with intact soma).
    explanation: >-
      The review distinguishes loss of precursor cells from loss of their processes; it synthesizes human pathology
      and experimental mechanisms.
- name: Oligodendrocyte Maturation Failure
  description: >-
    Regenerating oligodendroglial progenitors fail to complete differentiation into mature myelin-producing cells
    after premature white-matter injury. The precise cause of this maturation disturbance remains unresolved.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: oligodendrocyte differentiation
    term:
      id: GO:0048709
      label: oligodendrocyte differentiation
    modifier: DECREASED
  downstream:
  - target: White Matter Hypomyelination
    causal_link_type: DIRECT
    description: >-
      An inadequate mature oligodendrocyte population impairs subsequent myelination.
    evidence:
    - *id003
  evidence:
  - *id003
- name: White Matter Hypomyelination
  description: >-
    Reduced myelination is a developmental consequence of oligodendroglial injury and maturation failure in diffuse
    PVL. It is not synonymous with cystic destruction of motor tracts or sufficient by itself to diagnose cerebral
    palsy.
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: DECREASED
  locations:
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  evidence:
  - *id003
- name: Mitochondrial Energy Production Failure
  description: >-
    Mitochondrial energy production is impaired during neonatal hypoxic-ischemic injury.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:32112349
    reference_title: "Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."
    explanation: Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.
- name: Glutamate Excitotoxicity
  description: >-
    Excessive glutamatergic signaling contributes to hypoxic-ischemic cellular injury.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: glutamate receptor signaling pathway
    term:
      id: GO:0007215
      label: glutamate receptor signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:32112349
    reference_title: "Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."
    explanation: Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.
- name: Oxidative Cellular Injury
  description: >-
    Oxidative stress contributes to cellular injury after neonatal hypoxia-ischemia.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: PMID:32112349
    reference_title: "Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."
    explanation: Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.
- name: Neuronal Apoptosis
  description: >-
    Apoptotic neuronal loss is one component of neonatal hypoxic-ischemic injury.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
    modifier: DECREASED
  evidence:
  - reference: PMID:32112349
    reference_title: "Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."
    explanation: Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.
- name: Hypoxic-Ischemic Encephalopathy
  description: >-
    Neonatal hypoxia-ischemia produces encephalopathy and can injure the developing brain. Its cellular injury mechanisms
    are represented separately; not every affected newborn develops cerebral palsy.
  biological_scale: TISSUE
  downstream:
  - target: Mitochondrial Energy Production Failure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The HIE review identifies this cellular process within the injury response; no fixed ordering among these
      interacting mechanisms is asserted.
    evidence:
    - &id004
      reference: PMID:32112349
      reference_title: "Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HIE pathophysiology involves oxidative stress, mitochondrial energy production failure, glutaminergic excitotoxicity, and apoptosis."
      explanation: Review of neonatal HIE pathophysiology confirming energy failure, excitotoxicity, oxidative stress, and apoptosis as the injury cascade.
  - target: Glutamate Excitotoxicity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The HIE review identifies this cellular process within the injury response; no fixed ordering among these
      interacting mechanisms is asserted.
    evidence:
    - *id004
  - target: Oxidative Cellular Injury
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The HIE review identifies this cellular process within the injury response; no fixed ordering among these
      interacting mechanisms is asserted.
    evidence:
    - *id004
  - target: Neuronal Apoptosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The HIE review identifies this cellular process within the injury response; no fixed ordering among these
      interacting mechanisms is asserted.
    evidence:
    - *id004
  - target: Non-Progressive Developing-Brain Disturbance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Hypoxic-ischemic injury can leave a persistent developmental disturbance, with CP occurring in a subset of
      survivors.
    evidence:
    - reference: PMID:32086598
      reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        For babies born at term with neonatal encephalopathy or asphyxia, therapeutic hypothermia commenced within
        6-h of delivery is neuroprotective and prevents 15% of cerebral palsy associated with intrapartum hypoxia
      explanation: >-
        The review identifies CP associated with intrapartum hypoxia, rather than equating every episode of encephalopathy
        with CP.
  evidence:
  - *id004
- name: Perinatal Neuroinflammation
  description: >-
    Microglial activation accompanies inflammatory injury in the premature brain. Inflammation and ischemia can
    potentiate each other; experimental and neuropathological evidence implicates microglial mediators in vulnerable
    oligodendrocyte injury.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
    modifier: INCREASED
  biological_processes:
  - preferred_term: microglial cell activation
    term:
      id: GO:0001774
      label: microglial cell activation
    modifier: INCREASED
  - preferred_term: neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
    modifier: INCREASED
  downstream:
  - target: Premyelinating Oligodendrocyte Injury
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Microglial free radicals, cytokines and enhanced excitotoxicity contribute to injury of vulnerable pre-OLs
      in premature white matter.
    evidence:
    - &id005
      reference: PMID:19081519
      reference_title: 'Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Microglia seem to be key effectors of cellular injury with both ischaemia and inflammation.
      explanation: >-
        Mechanistic review supports microglia as injury effectors; this is not a causal inference from the chorioamnionitis
        association alone.
  evidence:
  - *id005
- name: Basal Ganglia and Thalamic Injury
  description: >-
    Deep gray-matter injury is an anatomic substrate associated with dyskinetic cerebral palsy. The motor phenotype
    depends on the affected circuits and accompanying lesions.
  biological_scale: TISSUE
  locations:
  - preferred_term: basal ganglia
    term:
      id: UBERON:0002420
      label: basal ganglion
  evidence:
  - &id006
    reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gray matter injury (21%) with thalamic and lentiform nuclear injury
    explanation: >-
      Table 2 associates this MRI pattern with the dyskinesia column; it does not establish the cause of every dyskinetic
      presentation.
  downstream:
  - target: Dystonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Deep gray-matter lesions can disrupt motor circuitry in dyskinetic CP; the diagnostic review supplies a clinical-imaging
      association.
    evidence:
    - *id006
- name: Bilirubin Encephalopathy (Kernicterus)
  description: >-
    Bilirubin-induced neurologic injury can produce the classical kernicterus syndrome, including athetoid cerebral
    palsy, impaired upward gaze and deafness.
  biological_scale: TISSUE
  evidence:
  - &id007
    reference: PMID:15578034
    reference_title: "Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "traditional and evolving definitions ranging from classical kernicterus with athetoid cerebral palsy, impaired upward gaze and deafness"
    explanation: Defines classical kernicterus (bilirubin encephalopathy) as producing athetoid (dyskinetic) cerebral palsy with impaired upgaze and deafness.
  - reference: PMID:15578034
    reference_title: Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      magnetic resonance imaging showing bilateral lesions of globus pallidus+/-subthalamic nucleus.
    explanation: >-
      The review describes deep-nuclear imaging findings in a proposed kernicterus case definition; this does not
      directly measure bilirubin deposition.
  notes: >-
    A distinct neonatal etiologic route. The cited clinical-spectrum review supports the syndrome and characteristic
    deep-nuclear imaging abnormalities; it does not directly demonstrate bilirubin deposition.
  locations:
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  downstream:
  - target: Choreoathetosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Classical kernicterus includes the athetoid motor phenotype.
    evidence:
    - *id007
- name: Secondary Musculoskeletal Pathology
  description: >-
    Contractures and progressive hip displacement may develop during growth despite a non-progressive underlying
    brain disturbance. Their course reflects multiple neuromuscular and biomechanical factors; reducing spasticity
    alone does not establish prevention of deformity.
  biological_scale: ORGANISM
  evidence:
  - &id008
    reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Contracture is a common complication, particularly for children with spastic cerebral palsy.
    explanation: >-
      Supports contracture as an evolving complication.
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One in three children in high-income countries experience progressive hip displacement as a complication of
      their cerebral palsy
    explanation: >-
      Supports progressive secondary hip pathology in the populations discussed.
  downstream:
  - target: Joint contractures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Secondary musculoskeletal change can restrict joint range.
    evidence:
    - *id008
  - target: Hip dislocation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Progressive displacement can culminate in dislocation; surveillance aims to prevent this outcome.
    evidence:
    - &id010
      reference: PMID:32086598
      reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        comprehensive multidisciplinary intervention (including botulinum toxin, weight-bearing, motor training,
        and
        orthopedic surgery) at the right time and the right dose can prevent hip dislocation
      explanation: >-
        The treatment review specifically discusses frank dislocation as a preventable complication; the broader
        displacement
        statistic is not assigned to this narrower phenotype.
- name: Genetically Mediated Neuritogenesis Disturbance
  description: >-
    A subset of CP-associated variants may disturb early neuronal process formation and circuit connectivity. This
    is a convergent mechanistic hypothesis from genetic and functional studies, not a proven common mechanism in
    all CP.
  biological_scale: CELLULAR
  mechanism_confidence: HYPOTHETICAL
  biological_processes:
  - preferred_term: neuron projection development
    term:
      id: GO:0031175
      label: neuron projection development
    modifier: ABNORMAL
  downstream:
  - target: Non-Progressive Developing-Brain Disturbance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Abnormal early neuronal connectivity is proposed to contribute to the developmental brain disturbance in genetically
      mediated CP.
    evidence:
    - &id009
      reference: PMID:32989326
      reference_title: Mutations disrupting neuritogenesis genes confer risk for cerebral palsy.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        we therefore predict that disruption of genes involved in neurodevelopmental patterning may alter early
        neuritogenesis and neuronal functional network connectivity in CP.
      explanation: >-
        The primary study integrates genetic, network and experimental evidence, but explicitly frames the neuronal-connectivity
        mechanism as a prediction.
  evidence:
  - *id009
phenotypes:
- name: Spasticity
  description: Velocity-dependent increase in muscle tone, the predominant motor abnormality in cerebral palsy.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:32989326
    reference_title: "Mutations disrupting neuritogenesis genes confer risk for cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Movement disorder (spasticity, dystonia, choreoathetosis and/or ataxia) onset occurs within the first few years of life as a manifestation of disrupted brain development"
    explanation: Enumerates spasticity as a core CP motor manifestation arising from disrupted brain development.
- name: Spastic diplegia
  subtype: Spastic
  description: >-
    Bilateral spastic motor impairment predominantly affecting the lower limbs.
  phenotype_term:
    preferred_term: Spastic diplegia
    term:
      id: HP:0001264
      label: Spastic diplegia
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      diplegia (lower limbs affected more than upper limbs)
    explanation: >-
      The early-diagnosis review describes this motor presentation.
- name: Spastic tetraplegia
  subtype: Spastic
  description: >-
    Bilateral spastic motor impairment involving all four limbs and the trunk.
  phenotype_term:
    preferred_term: Spastic tetraplegia
    term:
      id: HP:0002510
      label: Spastic tetraplegia
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      quadriplegia (all 4 limbs and trunk affected)
    explanation: >-
      The early-diagnosis review describes this motor presentation.
- name: Hemiplegia
  subtype: Spastic
  description: Unilateral motor impairment, often from perinatal arterial ischemic stroke.
  phenotype_term:
    preferred_term: Hemiplegia
    term:
      id: HP:0002301
      label: Hemiplegia
  evidence:
  - reference: PMID:20497457
    reference_title: "Epilepsy in hemiplegic cerebral palsy due to perinatal arterial ischaemic stroke."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the frequency, risk factors, manifestations, and outcome of epilepsy in children with hemiplegic cerebral palsy (CP) due to perinatal arterial ischaemic stroke (AIS)"
    explanation: Population-based CP-register study of hemiplegic CP caused by perinatal arterial ischemic stroke.
- name: Dystonia
  subtype: Dyskinetic
  description: Sustained or intermittent involuntary muscle contractions causing abnormal postures.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:32989326
    reference_title: "Mutations disrupting neuritogenesis genes confer risk for cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Movement disorder (spasticity, dystonia, choreoathetosis and/or ataxia) onset occurs within the first few years of life as a manifestation of disrupted brain development"
    explanation: Lists dystonia among the core CP movement-disorder manifestations.
- name: Choreoathetosis
  subtype: Dyskinetic
  description: Involuntary writhing (athetoid) and irregular jerky (choreic) movements seen in dyskinetic cerebral palsy.
  phenotype_term:
    preferred_term: Athetosis
    term:
      id: HP:0002305
      label: Athetosis
  evidence:
  - reference: PMID:32989326
    reference_title: "Mutations disrupting neuritogenesis genes confer risk for cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Movement disorder (spasticity, dystonia, choreoathetosis and/or ataxia) onset occurs within the first few years of life as a manifestation of disrupted brain development"
    explanation: Lists choreoathetosis among the core CP movement-disorder manifestations.
- name: Ataxia
  subtype: Ataxic
  description: Impaired balance and coordination from cerebellar dysfunction.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:32989326
    reference_title: "Mutations disrupting neuritogenesis genes confer risk for cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Movement disorder (spasticity, dystonia, choreoathetosis and/or ataxia) onset occurs within the first few years of life as a manifestation of disrupted brain development"
    explanation: Lists ataxia among the core CP movement-disorder manifestations.
- name: Hypotonia
  description: >-
    Reduced muscle tone is a recognized motor presentation; subtype terminology differs between classification systems.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hypotonia (2%), which is not classified in all countries
    explanation: >-
      The early-diagnosis review describes this motor presentation.
- name: Delayed gross motor development
  description: Delayed attainment of motor milestones is a core early feature prompting evaluation.
  phenotype_term:
    preferred_term: Delayed gross motor development
    term:
      id: HP:0002194
      label: Delayed gross motor development
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      parents, caregivers, or community-based professionals first notice delayed motor milestones
    explanation: >-
      Delayed milestones are a presenting diagnostic signal.
- name: Gait disturbance
  description: Abnormal gait patterns (e.g., scissoring, toe-walking, crouch gait) result from spasticity and contractures.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
- name: Intellectual disability
  description: Cognitive impairment accompanies motor disability in a substantial proportion of children with cerebral palsy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:23045562
    reference_title: "Clinical prognostic messages from a systematic review on cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1 in 2 had an intellectual disability"
    explanation: Population-based systematic review quantifying intellectual disability in ~50% of children with CP (FREQUENT band).
- name: Seizures
  description: Epilepsy is a common comorbidity, most frequent in spastic quadriplegia and hemiplegia.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:23045562
    reference_title: "Clinical prognostic messages from a systematic review on cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1 in 4 had epilepsy"
    explanation: Population-based systematic review quantifying epilepsy in ~25% of children with CP (OCCASIONAL band).
- name: Chronic pain
  description: Pain is the single most common comorbidity of cerebral palsy, arising from spasticity, contractures, hip displacement, and musculoskeletal deformity.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Pain
    term:
      id: HP:0012531
      label: Pain
  evidence:
  - reference: PMID:23045562
    reference_title: "Clinical prognostic messages from a systematic review on cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "3 in 4 were in pain"
    explanation: Population-based systematic review quantifying pain in ~75% of children with CP — the most common comorbidity (FREQUENT band).
- name: Visual impairment
  description: Cerebral/cortical and ocular visual impairment, ranging from refractive error and strabismus to blindness.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:23045562
    reference_title: "Clinical prognostic messages from a systematic review on cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1 in 10 were blind"
    explanation: Population-based systematic review; ~10% of children with CP are blind, the severe end of the visual-impairment spectrum. (Frequency band omitted because the statistic quantifies blindness, a narrower phenotype than the annotated HP term.)
- name: Hearing impairment
  description: Sensorineural hearing loss, notably in kernicterus-related dyskinetic CP (auditory neuropathy).
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:23045562
    reference_title: "Clinical prognostic messages from a systematic review on cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1 in 25 were deaf"
    explanation: Population-based systematic review; ~4% of children with CP are deaf, the severe end of the hearing-impairment spectrum. (Frequency band omitted because the statistic quantifies deafness, a narrower phenotype than the annotated HP term.)
- name: Absent speech
  description: >-
    Some children cannot communicate through speech. This finding does not by itself distinguish motor speech impairment
    from language or cognitive impairment.
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:23045562
    reference_title: "Clinical prognostic messages from a systematic review on cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1 in 4 could not talk"
    explanation: >-
      The review reports inability to talk in approximately one quarter; it does not establish dysarthria or anarthria
      as the cause.
  frequency: OCCASIONAL
- name: Dysphagia
  description: Swallowing difficulty, contributing to feeding problems, aspiration risk, and poor growth.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Half of all children with cerebral palsy have dysphagia and the prevalence is even higher in the infant population
    explanation: >-
      The systematic review reports swallowing impairment as a frequent associated problem.
  frequency: FREQUENT
- name: Drooling
  description: Sialorrhea from impaired oromotor control.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Drooling
    term:
      id: HP:0002307
      label: Drooling
  evidence:
  - reference: PMID:23045562
    reference_title: "Clinical prognostic messages from a systematic review on cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1 in 5 dribbled; 1 in 10 were blind"
    explanation: Population-based systematic review; ~20% (1 in 5) of children with CP drool/dribble (sialorrhea), supporting the OCCASIONAL band. (The trailing clause is contiguous list context from the same sentence.)
- name: Strabismus
  description: Ocular misalignment is a frequent associated visual impairment.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
- name: Scoliosis
  description: Neuromuscular scoliosis develops as a secondary musculoskeletal complication.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      infants with bilateral cerebral palsy who receive regular surveillance and intervention have lower rates of
      hip displacement, contracture, and scoliosis
    explanation: >-
      The review identifies scoliosis as a secondary complication in bilateral CP.
- name: Joint contractures
  description: >-
    Fixed restriction of joint movement develops as a secondary musculoskeletal complication, especially in spastic
    CP.
  phenotype_term:
    preferred_term: Joint contracture
    term:
      id: HP:0034392
      label: Joint contracture
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Contracture is a common complication, particularly for children with spastic cerebral palsy.
    explanation: >-
      Supports contracture as an evolving complication.
- name: Hip dislocation
  description: Spastic hip displacement and dislocation, a common orthopedic complication in non-ambulant children.
  phenotype_term:
    preferred_term: Hip dislocation
    term:
      id: HP:0002827
      label: Hip dislocation
  evidence:
  - *id010
- name: Behavioral abnormality
  description: Behavioral and emotional disorders are a common associated comorbidity in children with cerebral palsy.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Behavioral abnormality
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:23045562
    reference_title: "Clinical prognostic messages from a systematic review on cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1 in 4 had a behavior disorder"
    explanation: Population-based systematic review quantifying a behavior disorder in ~25% of children with CP (OCCASIONAL band).
- name: Sleep disturbance
  description: Sleep disorders are a recognized associated comorbidity in cerebral palsy.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:23045562
    reference_title: "Clinical prognostic messages from a systematic review on cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1 in 5 had a sleep disorder"
    explanation: Population-based systematic review quantifying a sleep disorder in ~20% of children with CP (OCCASIONAL band).
- name: Bladder control problems
  description: >-
    Bladder control difficulties are reported in children with CP; the pooled source does not specify a urinary
    dysfunction subtype.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Bladder control problems
    term:
      id: HP:0000009
      label: Functional abnormality of the bladder
    coarse_binding_basis: SOURCE_UNSPECIFIED
  evidence:
  - reference: PMID:23045562
    reference_title: Clinical prognostic messages from a systematic review on cerebral palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      1 in 4 had bladder control problems
    explanation: >-
      The review reports the broad finding in one quarter, without establishing a specific mechanism or urinary
      subtype.
environmental:
- name: Preterm birth and low birth weight
  influences_mechanisms:
  - target: Periventricular White Matter Injury
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Developmental vulnerability of premature white matter predisposes to injury; prematurity does not invariably
      trigger a lesion.
    evidence:
    - reference: PMID:19081519
      reference_title: 'Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Various maturation-dependent factors, including a propensity for premature infants to experience episodes
        of cerebral ischaemia and infection or inflammation, and an intrinsic susceptibility to excitotoxicity and
        free-radical accumulation, converge to accentuate vulnerability.
      explanation: >-
        Mechanistic review supports developmental susceptibility in premature white matter.
  description: >-
    CP risk rises with decreasing gestational age and birth weight. Premature white matter is developmentally vulnerable
    to injury.
  evidence:
  - reference: PMID:23346889
    reference_title: "An update on the prevalence of cerebral palsy: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of CP expressed by gestational age was highest in children born before 28 weeks' gestation (111.80 per 1000 live births; 95% CI 69.53-179.78; p<0.0327)."
    explanation: >-
      Supports the high CP prevalence in children born before 28 weeks; this association does not itself prove a
      specific cellular mechanism.
  - reference: PMID:19081519
    reference_title: "Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain injury in premature infants is of enormous public health importance because of the large number of such infants who survive with serious neurodevelopmental disability, including major cognitive deficits and motor disability."
    explanation: Links premature brain injury to the motor disability that manifests as cerebral palsy.
- name: Perinatal asphyxia / hypoxic-ischemic insult
  influences_mechanisms:
  - target: Hypoxic-Ischemic Encephalopathy
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Inadequate oxygen delivery during the neonatal period can cause hypoxic-ischemic brain injury.
    evidence:
    - reference: PMID:32112349
      reference_title: "Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hypoxic-ischemic encephalopathy, also referred as HIE, is a type of brain injury or damage that is caused by a lack of oxygen to the brain during neonatal period."
      explanation: >-
        States that the injury is caused by a lack of oxygen to the brain during
        the neonatal period, which is the causal claim this link makes rather
        than merely a definition of the entity.
  description: >-
    A hypoxic-ischemic insult around birth can cause neonatal encephalopathy, one recognized etiologic pathway to
    CP.
  evidence:
  - reference: PMID:32112349
    reference_title: "Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypoxic-ischemic encephalopathy, also referred as HIE, is a type of brain injury or damage that is caused by a lack of oxygen to the brain during neonatal period."
    explanation: >-
      States that the injury is caused by a lack of oxygen to the brain during
      the neonatal period, which is the causal claim this link makes rather
      than merely a definition of the entity.
- name: Intrauterine infection and inflammation
  influences_mechanisms:
  - target: Perinatal Neuroinflammation
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Maternal intrauterine infection can initiate inflammation relevant to premature brain injury.
    evidence:
    - reference: PMID:19081519
      reference_title: 'Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The main initiating pathogenetic mechanisms are ischaemia and inflammation, the latter often due to maternal
        intrauterine infection or postnatal sepsis.
      explanation: >-
        Review of premature brain injury supports inflammation after maternal intrauterine infection as an initiating
        route.
  description: >-
    Chorioamnionitis is associated with increased CP risk. This epidemiologic association is distinct from the mechanistic
    evidence concerning inflammatory brain injury.
  evidence:
  - reference: PMID:10989405
    reference_title: "Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among full-term infants, a positive association was found between clinical chorioamnionitis and cerebral palsy (RR, 4.7; 95% CI, 1.3-16.2)."
    explanation: Meta-analysis quantifying the association between chorioamnionitis and CP in full-term infants.
- name: Perinatal stroke
  influences_mechanisms:
  - target: Non-Progressive Developing-Brain Disturbance
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Perinatal arterial ischemic stroke can leave a persistent focal lesion and unilateral motor impairment.
    evidence:
    - reference: PMID:20497457
      reference_title: "Epilepsy in hemiplegic cerebral palsy due to perinatal arterial ischaemic stroke."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "children with hemiplegic cerebral palsy (CP) due to perinatal arterial ischaemic stroke (AIS)"
      explanation: >-
        Describes hemiplegic cerebral palsy arising from perinatal arterial
        ischaemic stroke, a focal fixed lesion.
  description: >-
    Perinatal arterial ischemic stroke is a recognized cause of unilateral cerebral palsy.
  evidence:
  - reference: PMID:20497457
    reference_title: "Epilepsy in hemiplegic cerebral palsy due to perinatal arterial ischaemic stroke."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "children with hemiplegic cerebral palsy (CP) due to perinatal arterial ischaemic stroke (AIS)"
    explanation: Links perinatal arterial ischemic stroke to hemiplegic cerebral palsy.
- name: Neonatal hyperbilirubinemia (kernicterus)
  influences_mechanisms:
  - target: Bilirubin Encephalopathy (Kernicterus)
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Severe neonatal bilirubin toxicity can produce the kernicterus syndrome, including athetoid cerebral palsy.
    evidence:
    - reference: PMID:15578034
      reference_title: "Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "classical kernicterus with athetoid cerebral palsy, impaired upward gaze and deafness"
      explanation: >-
        Describes classical kernicterus with athetoid cerebral palsy, impaired
        upward gaze and deafness, the clinical syndrome this node represents.
  description: >-
    Neonatal bilirubin toxicity is a recognized cause of the classical kernicterus syndrome, which includes athetoid
    cerebral palsy.
  evidence:
  - reference: PMID:15578034
    reference_title: "Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "classical kernicterus with athetoid cerebral palsy, impaired upward gaze and deafness"
    explanation: Identifies severe neonatal hyperbilirubinemia (kernicterus) as a cause of athetoid cerebral palsy.
- name: Multiple gestation and intrauterine growth restriction
  description: >-
    Twin/multiple pregnancies and fetal growth restriction carry elevated risk.
  evidence:
  - reference: PMID:21860286
    reference_title: Epidemiologic associations with cerebral palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Preterm birth, intrauterine growth restriction, perinatal infection, and multiple birth present the largest risks for a cerebral palsy outcome."
    explanation: >-
      Places both halves of this entry, intrauterine growth restriction and
      multiple birth, among the largest risks for cerebral palsy, alongside the
      preterm birth and perinatal infection exposures curated separately here.
  - reference: PMID:26003063
    reference_title: "Cerebral palsy: causes, pathways, and the role of genetic variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased risk is associated with preterm delivery, congenital malformations, intrauterine infection, fetal growth restriction, multiple pregnancy, and placental abnormalities."
    explanation: >-
      Independent review listing fetal growth restriction and multiple pregnancy
      among the exposures that raise cerebral palsy risk.
genetic:
- name: Monogenic and de novo genetic contributions
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Sequence variants and copy-number variants contribute to a subset of clinically ascertained CP. Diagnostic yields
    depend on cohort selection and variant interpretation; they do not establish one genetic cause across this heterogeneous
    syndrome.
  evidence:
  - reference: PMID:32989326
    reference_title: "Mutations disrupting neuritogenesis genes confer risk for cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found an enrichment of damaging DNMs in CP cases, which became more apparent when focusing the analysis on genes intolerant to LoF variation"
    explanation: Whole-exome sequencing of 250 CP trios shows enrichment of damaging de novo mutations, implicating monogenic genetic contributions (e.g., CTNNB1, TUBA1A).
  - reference: PMID:30564460
    reference_title: "Pathogenic copy number variants that affect gene expression contribute to genomic burden in cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Combined SNV and CNV analysis revealed pathogenic and likely pathogenic variants in 22.7% of unselected individuals with CP."
    explanation: >-
      Combined prior sequence-variant analyses with the CNV analysis of an unselected Australian CP cohort. The
      full text reports seven additional cases among 186 analyzed (3.7%) and a combined yield of 22.7%; this is
      not a universal CP prevalence estimate.
  - reference: PMID:38553553
    reference_title: Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Multiple classes of P/LP variants included single-nucleotide variants (SNVs)/indels (6.7%), copy number variations
      (3.4%) and mitochondrial mutations (1.5%).
    explanation: >-
      The whole-genome cohort illustrates variant-class diversity; these are cohort-specific yields and categories
      need not be mutually exclusive.
- name: CTNNB1
  gene_term:
    preferred_term: CTNNB1
    term:
      id: hgnc:2514
      label: CTNNB1
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    Damaging de novo CTNNB1 variants were enriched in a CP-ascertained trio cohort, and affected individuals had
    spasticity, intellectual disability and language disorders. CTNNB1-related neurodevelopmental disorder provides
    an etiologic diagnosis in these individuals. The CP label did not identify a distinct subgroup in a later CTNNB1
    cohort. The relationship applies to the clinically ascertained subset rather than to CP generally; its representation
    alongside the molecular diagnosis remains a classification question.
  evidence:
  - reference: PMID:32989326
    reference_title: Mutations disrupting neuritogenesis genes confer risk for cerebral palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CTNNB1, encoding β-catenin, harbors three LoF DNMs
    explanation: >-
      Primary results identify loss-of-function de novo variants in CP-ascertained individuals.
  - reference: PMID:36083290
    reference_title: Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In summary, individuals with P/LP CTNNB1 variants were similarly affected irrespective of their CP diagnosis.
    explanation: >-
      The later phenotype comparison does not support CP as a separate CTNNB1 molecular subgroup.
- name: TUBA1A
  gene_term:
    preferred_term: TUBA1A
    term:
      id: hgnc:20766
      label: TUBA1A
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    Recurrent de novo TUBA1A variants reached genome-wide significance in a
    whole-exome study of CP trios; TUBA1A encodes a neuronal alpha-tubulin
    essential for neuronal migration.
  evidence:
  - reference: PMID:32989326
    reference_title: "Mutations disrupting neuritogenesis genes confer risk for cerebral palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "of these, two (TUBA1AandCTNNB1) met genome-wide significance."
    explanation: Recurrent damaging de novo mutations in TUBA1A (and CTNNB1) reached genome-wide significance in CP trios.
treatments:
- name: Physical therapy
  description: >-
    Active, goal-directed practice of meaningful motor tasks, with strength or mobility training selected for the
    specific functional goal. Improvements in strength or tone should not be assumed to generalize automatically
    to activity or participation.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      practice of real-life tasks and activities, using self-generated active movements, at a high intensity
    explanation: >-
      The full text identifies active practice as a shared feature of effective motor interventions.
- name: Occupational therapy
  description: >-
    Goal-directed practice of daily activities and hand use. Constraint-induced movement therapy and bimanual training
    are evidence-supported approaches, particularly for unilateral motor impairment; goals and tasks are individualized.
  treatment_term:
    preferred_term: occupational therapy
    term:
      id: NCIT:C121351
      label: Occupational Therapy
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Substantive clinical trial data support the efficacy of training-based interventions
    explanation: >-
      The review details bimanual, constraint-induced, goal-directed and other active training approaches.
- name: Speech and language therapy
  description: >-
    Individualized communication support, including augmentative and alternative communication when speech is inadequate;
    feeding and swallowing difficulties require specific assessment.
  treatment_term:
    preferred_term: speech and language therapy
    term:
      id: NCIT:C159273
      label: Speech Language Therapy
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      provide compensation when speech is not possible or is inadequate
    explanation: >-
      The early-intervention recommendations support communication alternatives.
- name: Botulinum toxin injection
  description: Intramuscular botulinum toxin type A for focal spasticity and dystonia.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: botulinum toxin type A
      term:
        id: CHEBI:3160
        label: Botulinum toxin type A
  therapeutic_modality: OTHER
  evidence:
  - reference: PMID:32086598
    reference_title: "State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Effective medical and surgical interventions include anti-convulsants, bisphosphonates, botulinum toxin, botulinum toxin plus occupational therapy, botulinum toxin plus casting, diazepam, dentistry, hip surveillance, intrathecal baclofen, scoliosis correction, selective dorsal rhizotomy, and umbilical cord blood cell therapy."
    explanation: Systematic-review traffic-light appraisal listing botulinum toxin among effective CP interventions.
- name: Intrathecal baclofen
  description: >-
    Intrathecal baclofen can reduce spasticity. The cited systematic-review evidence is route-specific and does
    not establish efficacy of oral baclofen or functional gains from tone reduction alone.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: baclofen
      term:
        id: CHEBI:2972
        label: baclofen
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:32086598
    reference_title: "State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Effective medical and surgical interventions include anti-convulsants, bisphosphonates, botulinum toxin, botulinum toxin plus occupational therapy, botulinum toxin plus casting, diazepam, dentistry, hip surveillance, intrathecal baclofen, scoliosis correction, selective dorsal rhizotomy, and umbilical cord blood cell therapy."
    explanation: Systematic-review traffic-light appraisal listing intrathecal baclofen among effective CP interventions.
- name: Selective dorsal rhizotomy
  description: >-
    Neurosurgical sectioning of selected dorsal (sensory) nerve rootlets to
    reduce lower-limb spasticity in carefully selected ambulant children with
    spastic diplegia.
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  therapeutic_modality: SURGERY
  evidence:
  - reference: PMID:32086598
    reference_title: "State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Effective medical and surgical interventions include anti-convulsants, bisphosphonates, botulinum toxin, botulinum toxin plus occupational therapy, botulinum toxin plus casting, diazepam, dentistry, hip surveillance, intrathecal baclofen, scoliosis correction, selective dorsal rhizotomy, and umbilical cord blood cell therapy."
    explanation: Systematic-review traffic-light appraisal listing selective dorsal rhizotomy among effective CP interventions.
- name: Orthopedic surgery
  description: >-
    Muscle-tendon lengthening, hip reconstruction, and scoliosis correction for
    established musculoskeletal deformities.
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  therapeutic_modality: SURGERY
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Once a contracture is severe (e.g., greater than 20°) and longstanding, casting will no longer be sufficient
      in isolation, and orthopedic surgery requires consideration.
    explanation: >-
      The review discusses surgery for established contracture with individualized timing and functional assessment.
- name: Supportive and multidisciplinary care
  description: >-
    Coordinated management including orthoses, assistive devices, nutrition,
    management of epilepsy, pain, and orthopedic surveillance (e.g., hip
    surveillance programs).
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: OTHER
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      prevent secondary impairments and minimize the influence of complications that worsen function or interfere
      with learning
    explanation: >-
      The review recommends care addressing associated impairments and secondary complications.
- name: Antenatal magnesium sulfate (fetal neuroprotection)
  description: >-
    Magnesium sulfate given to women at risk of imminent preterm birth reduces
    the risk of cerebral palsy in the offspring. This is an established antenatal
    neuroprotective (preventive) intervention, not a treatment of established CP.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: magnesium sulfate
      term:
        id: CHEBI:32599
        label: magnesium sulfate
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:39724363
    reference_title: "Magnesium sulfate for fetal neuroprotection in preterm labor: an updated systematic review and meta-analysis of randomized controlled trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our meta-analysis including eight RCTs showed that magnesium sulfate reduced the risk of cerebral palsy without a significant change in pediatric mortality."
    explanation: Meta-analysis of RCTs showing antenatal magnesium sulfate reduces CP risk in preterm-labor pregnancies.
  - reference: PMID:32086598
    reference_title: "State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Effective prevention strategies include antenatal corticosteroids, magnesium sulfate, caffeine, and neonatal hypothermia."
    explanation: Systematic review listing antenatal magnesium sulfate among effective CP prevention strategies.
  - reference: PMID:39724363
    reference_title: 'Magnesium sulfate for fetal neuroprotection in preterm labor: an updated systematic review and meta-analysis of randomized controlled trials.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The effect of antenatal administration of MgSO4 showed no significant effect on the composite primary outcome
      of pediatric mortality and CP.
    explanation: >-
      The full-text discussion distinguishes the CP outcome from the composite endpoint.
  notes: >-
    The 2025 meta-analysis found no significant effect on the composite of pediatric mortality and CP. Regimens
    and gestational ages differed across trials, and long-term follow-up was limited; the pooled reduction in CP
    should not be interpreted as evidence of benefit at every gestational age.
- name: Therapeutic hypothermia (neonatal neuroprotection)
  description: >-
    Whole-body or selective head cooling initiated within 6 hours of birth in
    term/late-preterm newborns with moderate-to-severe hypoxic-ischemic
    encephalopathy reduces death and long-term neurodevelopmental disability,
    including cerebral palsy. This is a preventive neuroprotective intervention
    applied in the neonatal period, not a treatment of established CP.
  treatment_term:
    preferred_term: Therapeutic Procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  therapeutic_modality: OTHER
  evidence:
  - reference: PMID:23440789
    reference_title: "Cooling for newborns with hypoxic ischaemic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is evidence from the 11 randomised controlled trials included in this systematic review (N = 1505 infants) that therapeutic hypothermia is beneficial in term and late preterm newborns with hypoxic ischaemic encephalopathy."
    explanation: Cochrane meta-analysis showing cooling reduces death and neurodevelopmental disability after neonatal HIE, a major cause of CP.
- name: Hip surveillance
  description: >-
    Structured surveillance with timely multidisciplinary assessment and intervention aims to detect displacement
    early and prevent dislocation. Surveillance benefit should not be attributed to any single tone-reducing treatment.
  treatment_term:
    preferred_term: hip surveillance
  therapeutic_modality: OTHER
  notes: >-
    Deliberately left unbound; the meaning is carried in preferred_term. TreatmentActionTerm is rooted at
    NCIT:C25218 Clinical Intervention or Procedure. The OLS search API for "hip surveillance" in NCIT returns no
    hits; "surveillance" returns NCIT:C15719 Surveillance as the top hit, and its OLS hierarchicalAncestors are
    Observational Study, Clinical Study, Study, Research Activity and Activity, with no NCIT:C25218 among them.
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There is moderate-quality evidence and a strong recommendation to use comprehensive hip surveillance practices
      to facilitate early detection and management of hip displacement
    explanation: >-
      The review supports comprehensive surveillance and response to findings.
- name: Antenatal corticosteroids
  description: >-
    Antenatal corticosteroids in the preterm-birth setting reduce intracranial hemorrhage and provide fetal neuroprotection.
    This is prevention in a selected obstetric population, not treatment of established CP.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: corticosteroid
      term:
        id: CHEBI:50858
        label: corticosteroid
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antenatal corticosteroids decrease intracranial hemorrhage and thereby also act as an effective neuroprotectant
    explanation: >-
      The full systematic review supports this intervention within the specified clinical context.
- name: Neonatal caffeine
  description: >-
    Caffeine in selected mechanically ventilated premature infants is a neonatal preventive strategy. This evidence
    does not support caffeine as a treatment for established CP.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: caffeine
      term:
        id: CHEBI:27732
        label: caffeine
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Once an infant is born preterm and is mechanically ventilated, prophylactic caffeine (methylxanthines) prior
      to extubation effectively prevents cerebral palsy
    explanation: >-
      The full systematic review supports this intervention within the specified clinical context.
- name: Diazepam for spasticity
  description: >-
    Diazepam can reduce spasticity. Treatment goals and tolerability require individualized assessment; reduced
    tone does not itself establish improved mobility.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: diazepam
      term:
        id: CHEBI:49575
        label: diazepam
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Effective medical and surgical interventions include anti-convulsants, bisphosphonates, botulinum toxin, botulinum toxin plus occupational therapy, botulinum toxin plus casting, diazepam, dentistry, hip surveillance, intrathecal baclofen, scoliosis correction, selective dorsal rhizotomy, and umbilical cord blood cell therapy."
    explanation: >-
      The systematic review lists diazepam among the medical interventions it graded as effective.
animal_models:
- name: Developmental xenocortication with human cortical organoids (XCX)
  species: Mouse
  genotype: Emx1-cre+/−; Esco2fl/fl; Prkdcscid/scid
  background: Immunodeficient SCID host with neonatal human cortical organoid engraftment.
  publication: PMID:42749812
  description: >-
    Platform for studying developing human cortical cells, circuit integration and host behaviour
    in vivo. Conditional Esco2 deletion in the Emx1 lineage depletes mouse neocortical and
    hippocampal glutamatergic neurons, creating space for human stem-cell-derived cortical
    organoids. The grafts grow extensively, generate diverse cortical cell types and exhibit
    organized activity. Hypoxic injury to the developing human graft is a proof-of-concept
    application. The authors identify perinatal hypoxia and associated cerebral palsy as potential
    future modelling applications; this record does not establish XCX mice as a validated
    model of cerebral palsy.
  associated_phenotypes:
  - Human graft HIF1α immunoreactivity after hypoxia
  - Increased intragraft astroglial and microglial density and altered morphology after hypoxia
  - Enhanced graft vascular hypointensities on susceptibility-weighted MRI after hypoxia
  - Altered mouse paw-support strategy and hindpaw contact after hypoxia
  notes: >-
    Figure 5 uses 5% O2 for 5 hours, preceded by a 1-hour graded descent, as specified by
    the figure legend and Methods. HIF1α was assessed immediately after exposure and SWI at
    10 days; each finding was reported in three XCX mice. Glial measurements at 20 days compared
    four normoxic and four hypoxia-exposed XCX mice. GFAP-positive astroglia were human graft-derived;
    IBA1-positive microglia were mouse host-derived. CatWalk measurements compared each animal
    at baseline and two days after injury: 11 control, nine apallial and nine XCX mice. The
    apallial hypoxia group contained only females, preventing a complete sex-by-genotype analysis.
    Reported gait changes were not accompanied by detected group differences in running-speed
    or step-cadence changes; this is not an equivalence result. Esco2 deletion is host engineering,
    not evidence for an ESCO2 cause of cerebral palsy. Mechanism links are deliberately unassigned:
    the existing hypoxic-ischemic encephalopathy node includes mechanisms not established
    by this hypoxia experiment, and the perinatal neuroinflammation node describes a different
    initiating context. Acute behavioural readouts do not establish a permanent motor disorder.
    Graft-neuron necessity or sufficiency for specific behaviours remains unresolved. These
    model observations are not added as human phenotypes.
  evidence:
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Here we establish a transplantation platform using a genetic strategy to effectively
      deplete glutamatergic neurons from mouse neocortex and hippocampus (apallial) and neonatally
      engraft the cortical cavity with human stem-cell-derived cortical organoids (hCO) to
      generate xenocortical mice.
    explanation: Establishes the platform design and the human graft in an apallial mouse host.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      This leads to robust graft growth with hCOs occupying most of the cortical volume and
      generating a diversity of human cortical cell types, including layer 5 extratelencephalic
      projection neurons.
    explanation: Supports graft expansion and cortical cell-type diversity as platform characteristics.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Human cortical neurons integrate with the mouse nervous system, and in vivo cortical
      graft-wide calcium imaging and electrophysiological analyses revealed patterns of organized
      activity resembling developing circuits.
    explanation: >-
      Reports organized graft activity and integration; it does not demonstrate that graft
      neurons cause particular host behaviours.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We deleted the sister chromatid cohesion factor Esco2 specifically in cells expressing
      the dorsal and medial pallium marker Emx1 in an immunocompromised SCID background4,5,6
      (apallial mice: Emx1-cre+/−Esco2fl/flPrkdcscid/scid;
    explanation: Identifies the conditional host genotype and SCID background used to generate the platform.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mice were exposed to 5% O2 for 5 h preceded by a 1 h run-in period during which the
      oxygen percentage was gradually decreased to the 5% target.
    explanation: Figure 5 legend specifies five hours at the target oxygen concentration after the one-hour run-in.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In 3 out of 3 XCX mice exposed to 5% O2 for 5 h, HIF1α immunoreactivity was detected
      in the human graft, whereas HIF1α signal was not appreciable in the adjacent mouse palaeocortex
    explanation: >-
      Reports the immediate HIF1α response localized to the human graft. This is a hypoxia-response
      measurement, not direct evidence of neuronal death.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      A comparison of SWI sequences of the same mice at baseline and 10 days after injury
      revealed enhanced hypointense vasculature in 3 out of 3 XCX mice exposed to 5% O2 for
      5 h (Fig. 5c).
    explanation: >-
      Reports the within-animal vascular imaging change ten days after hypoxia in three XCX
      mice; the signal is a correlate, not a specific assay of ischemia or neuronal death.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Finally, we found that XCX mice exposed to 5% O2 for 5 h exhibited an increased density
      and complexity of intragraft microglia and astroglia (Fig. 5d–i)
    explanation: >-
      Reports increased intragraft glial density and complexity after hypoxia, without establishing
      that these changes mediate the gait effects.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      For assessment of the inflammatory response to hypoxic injury, intragraft GFAP+ (human,
      graft-derived) and IBA1+ (host-derived, mouse) cell density was analysed.
    explanation: The Methods distinguish human graft-derived GFAP-positive cells from mouse host-derived IBA1-positive cells.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      XCX mice showed the greatest increase from baseline in three- to four-paw support, adopting
      a more stable position than the more common two-paw position
    explanation: >-
      Reports the post-hypoxia mouse paw-support change; this is an acute model readout rather
      than a diagnosis of cerebral palsy.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      This was potentially driven by longer hindpaw contact duration, larger contact area
      and greater maximum print intensity on the glass surface (Fig. 5l,m and Extended Data
      Fig. 10h).
    explanation: >-
      Reports the accompanying hindpaw contact changes. The authors describe their contribution
      to paw support as potential, not causally established.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Critically, this phenotype was not associated with changes in overall running speed,
      step cadence or a non-specific increase of variability in the XCX group
    explanation: >-
      Preserves the reported negative locomotor findings in the tested cohort without treating
      lack of significance as proof of equivalence.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Representative immunostaining of intragraft GFAP in an XCX graft 20 days after injury
      (bottom left) and an age-matched normoxia XCX graft (top left) highlighting the density.
    explanation: Figure 5d places the glial assessment at 20 days after injury, with an age-matched normoxic graft comparator.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Quantification of intragraft GFAP+ cellular density. n = 4 (control XCX) and n = 4 (post-injury XCX) mice.
    explanation: Figure 5e reports four control and four post-injury XCX mice for astroglial density.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Quantification of intragraft IBA1+ cellular density. n = 4 (control XCX) and n = 4 (post-injury XCX) mice.
    explanation: Figure 5h reports four mice per condition for intragraft microglial density.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      CatWalk data for control (n = 6 female, 5 male), apallial (n = 9 female) and XCX (n = 4
      female, 5 male) mice. Each point represents the within-animal difference between performance
      at 2 days after injury and at the baseline; that is, values above zero indicate that
      the measurement was increased after injury.
    explanation: >-
      Figure 5j-n identifies 11 control, nine apallial and nine XCX mice, with the animal
      as the unit for the two-day post-injury versus baseline comparison.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Sex × genotype effects were not estimable in the hypoxic injury experiments because
      the apallial group contained only female mice.
    explanation: >-
      The hypoxia experiment cannot fully separate sex from genotype because all apallial
      mice in that comparison were female.
- name: Preterm fetal sheep cerebral ischemia
  species: Sheep
  publication: PMID:30149778
  description: >-
    Mid-gestation fetal sheep cerebral ischemia models premature white-matter injury and subsequent oligodendrocyte
    maturation failure.
  notes: >-
    Developmental stage and insult severity determine injury distribution. This model informs a proximal injury
    mechanism rather than reproducing the heterogeneous clinical CP syndrome. Intrauterine recovery differs from
    the human neonatal transition.
  modeled_mechanisms:
  - target: Oligodendrocyte Maturation Failure
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Progenitor proliferation without maturation after fetal cerebral ischemia models the maturation-failure component
      of premature white-matter injury.
    limitations: >-
      Developmental stage and ischemic severity constrain extrapolation to human CP; the model does not reproduce
      the full clinical syndrome.
    evidence:
    - reference: PMID:30149778
      reference_title: 'Perinatal hypoxic-ischemic brain injury in large animal models: Relevance to human neonatal encephalopathy.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        late progenitors proliferate but fail to mature into myelin producing oligodendrocytes after cerebral ischemia.
      explanation: >-
        The full-text fetal-sheep section reports maturation failure after ischemia.
discussions:
- discussion_id: xcx_hypoxia_translation_to_cerebral_palsy
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: Can hypoxic injury in the xenocortication platform model the persistent motor dysfunction of cerebral palsy?
  attaches_to:
  - animal_models#Mouse
  - pathophysiology#Non-Progressive Developing-Brain Disturbance
  rationale: >-
    The paper introduces a human cortical development and circuit platform and demonstrates
    hypoxic injury as an application. Its cerebral-palsy connection is prospective. The demonstrated
    cellular responses and short-term mouse gait changes do not establish the persistent human
    motor syndrome, the full hypoxic-ischemic injury cascade, or a causal chain from HIF1α
    through gliosis to impaired gait. Immature cortical organization, mixed human and mouse
    cellular contributions, and unresolved graft-specific behavioural causality constrain
    translation. Longitudinal motor assessment and graft-specific perturbations would be needed
    to assess that connection.
  evidence:
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      For example, XCX mice display gait deficits following hypoxic injury, highlighting the
      potential for modelling perinatal hypoxia and associated cerebral palsy49 as well as
      human neurodevelopmental disorders more broadly.
    explanation: >-
      The authors explicitly frame perinatal hypoxia and associated cerebral palsy as potential
      applications, supporting inclusion as a prospective connection.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The observed behavioural outputs probably reflect interactions between the human graft
      and preserved mouse subcortical circuits, but whether graft-derived neurons are necessary
      or sufficient for specific behaviours remains unclear.
    explanation: The authors leave graft-neuron necessity and sufficiency for behaviour unresolved.
  - reference: PMID:42749812
    reference_title: Developmental xenocortication using human-derived organoids in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      At the timepoints examined, the XCX graft lacked several features of mature cortical
      circuitry, including complete areal patterning, a well-defined laminar cortical plate,
      full representation of GABAergic interneurons and a mature transcriptional profile.
    explanation: Documents incomplete areal patterning, lamination, interneuron representation and transcriptional maturity.
- discussion_id: ctnnb1_clinical_umbrella_relationship
  kind: OPEN_QUESTION
  status: OPEN
  prompt: How should CTNNB1 causation be represented on the clinical CP umbrella alongside CTNNB1-related neurodevelopmental disorder?
  attaches_to:
  - genetic#CTNNB1
  rationale: >-
    Primary CP-ascertained evidence supports recurrent damaging CTNNB1 variants, whereas the larger CTNNB1 phenotype
    comparison does not identify a separate CP subgroup. The unresolved question is how to distinguish causation
    of the molecular disorder from its representation under a clinical motor-syndrome umbrella. See issue #11823.
  evidence:
  - reference: PMID:32989326
    reference_title: Mutations disrupting neuritogenesis genes confer risk for cerebral palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CTNNB1, encoding β-catenin, harbors three LoF DNMs
    explanation: >-
      Primary results identify loss-of-function de novo variants in CP-ascertained individuals.
  - reference: PMID:36083290
    reference_title: Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In summary, individuals with P/LP CTNNB1 variants were similarly affected irrespective of their CP diagnosis.
    explanation: >-
      The later phenotype comparison does not support CP as a separate CTNNB1 molecular subgroup.
notes: >-
  Cerebral palsy is a clinical umbrella for permanent disorders of movement and posture attributed to non-progressive
  disturbances in the developing brain. Etiologies include acquired injury and genetic developmental disorders.
  A progressive neurodegenerative disorder requires reconsideration of the CP diagnosis; a genetic finding alone
  does not. Functional domains are assessed separately, including GMFCS for gross motor function, MACS for manual
  ability, CFCS for communication and EDACS for eating and drinking. Secondary complications and functional needs
  can evolve despite the non-progressive underlying disturbance.
diagnosis:
- name: Clinical assessment with age-appropriate standardized tools
  description: >-
    Diagnosis integrates the movement and posture phenotype, developmental history, neurological examination and
    exclusion of a progressive disorder. Before five months corrected age, General Movements Assessment, HINE and
    MRI are complementary tools. A high-risk designation can support early intervention while diagnostic certainty
    develops.
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a combination of assessments with strong predictive validity coupled with clinical reasoning is recommended.
    explanation: >-
      Supports combined assessment rather than a single diagnostic test.
- name: Brain MRI
  description: >-
    MRI helps identify white-matter injury, deep gray-matter lesions, stroke or maldevelopment. Normal neuroimaging
    does not exclude clinical CP.
  diagnosis_term:
    preferred_term: brain magnetic resonance imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      approximately 10% have normal neuroimaging
    explanation: >-
      A normal scan cannot rule out the clinical syndrome.
- name: Etiologic genomic assessment
  description: >-
    Genomic testing can identify a molecular etiology and refine counseling. A pathogenic result and a clinical
    CP diagnosis can coexist when the phenotype meets CP criteria; progressive disorders require diagnostic reconsideration.
    Variants of uncertain significance do not establish an etiology.
  diagnosis_term:
    preferred_term: etiologic genomic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:38553553
    reference_title: Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We classified 37 of 327 (11.3%) children as having pathogenic/likely pathogenic (P/LP) variants
    explanation: >-
      The 327-trio whole-genome study supports a genetic diagnostic yield in a subset, not a universal genetic cause.
progression:
- phase: Evolving motor phenotype
  notes: >-
    The underlying disturbance is non-progressive, but motor type and functional severity can change during early
    development. Early severity predictions require caution.
  evidence:
  - reference: PMID:28715518
    reference_title: 'Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The motor types and topography of cerebral palsy may emerge and change during the first 2 years of life.
    explanation: >-
      Distinguishes evolution of the clinical phenotype from progressive neurodegeneration.
- phase: Secondary musculoskeletal complications
  notes: >-
    Contractures and hip displacement may progress during growth and require ongoing surveillance and individualized
    management.
  evidence:
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Contracture is a common complication, particularly for children with spastic cerebral palsy.
    explanation: >-
      Supports contracture as an evolving complication.
  - reference: PMID:32086598
    reference_title: 'State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One in three children in high-income countries experience progressive hip displacement as a complication of
      their cerebral palsy
    explanation: >-
      Supports progressive secondary hip pathology in the populations discussed.
clinical_trials:
- name: NCT06586437
  description: >-
    Cortical and spinal neuromodulation
  status: ACTIVE_NOT_RECRUITING
  evidence:
  - reference: clinicaltrials:NCT06586437
    reference_title: Neuromodulation of the Cortex and Spinal Cord
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Specific Aim 2: To investigate the effect of transcutaneous current stimulation applied over the cortex and/or
      spinal cord on the sensorimotor cortical activity, spinal cord dynamics, and corticospinal coherence.
    explanation: >-
      The registry summary states the planned intervention or comparison.
  notes: >-
    Registry status and design checked 2026-10-16; last registry update 2026-07-30. This entry records the study
    aim, not demonstrated efficacy.
  phase: NOT_APPLICABLE
- name: NCT05158218
  description: >-
    Robotic exoskeleton versus conventional gait training
  status: ACTIVE_NOT_RECRUITING
  evidence:
  - reference: clinicaltrials:NCT05158218
    reference_title: Robotic Exoskeleton Gait Training in Adolescents With Cerebral Palsy
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the participants with CP will undergo the therapeutic gait training using either traditional physical therapy
      or utilizing a robotic exoskeleton.
    explanation: >-
      The registry summary states the planned intervention or comparison.
  notes: >-
    Registry status and design checked 2026-10-16; last registry update 2026-05-28. This entry records the study
    aim, not demonstrated efficacy.
  phase: NOT_APPLICABLE
- name: NCT04360395
  description: >-
    Gait training with neuroimaging and neurophysiological outcome assessment
  status: ACTIVE_NOT_RECRUITING
  evidence:
  - reference: clinicaltrials:NCT04360395
    reference_title: Igniting Mobility in Adolescents and Young Adults With Cerebral Palsy
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      After completing all of the therapeutic gait training sessions, the participants with CP will repeat the same
      assessments that were completed at baseline.
    explanation: >-
      The registry summary states the planned intervention or comparison.
  notes: >-
    Registry status and design checked 2026-10-16; last registry update 2026-07-30. This entry records the study
    aim, not demonstrated efficacy.
  phase: NOT_APPLICABLE
- name: NCT04314687
  description: >-
    Umbilical-cord mesenchymal stromal cells with or without conditioned medium
  status: ACTIVE_NOT_RECRUITING
  evidence:
  - reference: clinicaltrials:NCT04314687
    reference_title: Allogeneic Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium for Cerebral Palsy in Children
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aim of this study was to compare the effectiveness of umbilical cord mesenchymal stem cells (UCMSCs) and
      conditioned medium (CM) administration, UCMSCs only and control with standard therapy.
    explanation: >-
      The registry summary states the planned intervention or comparison.
  notes: >-
    Registry status and design checked 2026-10-16; last registry update 2026-02-25. This entry records the study
    aim, not demonstrated efficacy. Registered as combined phase 1/2; the single-phase field is omitted to preserve
    that distinction.

📚

References & Deep Research

References

9

PMID:42749812

Developmental xenocortication using human-derived organoids in mice.

No top-level findings curated for this source.

PMID:17370477

A report: the definition and classification of cerebral palsy April 2006.

No top-level findings curated for this source.

PMID:23346889

An update on the prevalence of cerebral palsy: a systematic review and meta-analysis.

No top-level findings curated for this source.

PMID:32989326

Mutations disrupting neuritogenesis genes confer risk for cerebral palsy.

No top-level findings curated for this source.

PMID:32086598

State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.

No top-level findings curated for this source.

PMID:28715518

Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.

No top-level findings curated for this source.

PMID:30963790

Genetic or Other Causation Should Not Change the Clinical Diagnosis of Cerebral Palsy.

No top-level findings curated for this source.

PMID:38553553

Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy.

No top-level findings curated for this source.

PMID:30149778

Perinatal hypoxic-ischemic brain injury in large animal models: Relevance to human neonatal encephalopathy.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Cerebral Palsy · 2026-07-31T23:10:52Z · View source

Created new Cerebral Palsy MONDO:0006497 entry. First pass from textbook knowledge, then augmented with Edison Falcon deep research. Curated 4 motor subtypes, 8 pathophysiology nodes, 19 phenotypes with HPO terms, 6 environmental risk factors, a genetic de novo and monogenic contribution block, and 10 treatments including preventive antenatal magnesium sulfate and neonatal therapeutic hypothermia. 32 evidence items with exact-quote snippets validated against cached abstracts: Rosenbaum 2007 definition, Oskoui 2013 prevalence, Jin 2020 and Corbett 2018 genetics, Volpe 2009 PVL, Wu-Colford 2000 chorioamnionitis, Shapiro 2005 kernicterus, Novak 2020 treatment traffic-lights, Jafar 2024 MgSO4. Frequency bands backed by Novak 2012 comorbidity rates. Validated with just validate, all pass, 32 of 32 snippets verified.

Falcon ▸

Cerebral Palsy: Disease-Characteristics Research Report

Edison Scientific Literature 32 citations 2026-07-31T22:59:30.096907

Cerebral Palsy: Disease-Characteristics Research Report

Executive summary

Cerebral palsy (CP) is not one etiologic disease but a clinically defined, heterogeneous group of permanent movement and posture disorders caused by a non-progressive disturbance of the developing fetal or infant brain. The original lesion does not progress, although musculoskeletal complications, pain, fatigue, and functional limitations may change across life. Current evidence rejects the older assumption that CP is principally synonymous with intrapartum asphyxia: prematurity, congenital maldevelopment, stroke, infection/inflammation, placental disease, neonatal injury, and an increasingly important genomic component all contribute. A 2024 review reports prevalence of approximately 1.6 per 1,000 live births in high-income countries versus 3.3 per 1,000 in low- and middle-income countries. Common associated impairments include cognitive impairment (~50%), epilepsy (~33%), language impairment (~33%), and inability to walk independently (~40%). (xu2024geneticpathwaysin pages 1-1)

The most important recent development is genomic reclassification. A 2024 Nature Genetics study of 327 parent-child trios identified pathogenic/likely pathogenic variants in 37 children (11%) and variants of uncertain significance in 58 (18%). A separate meta-analytic estimate cited in a 2024 eBioMedicine review was 23% for single-nucleotide variants and 5% for copy-number variants. Thus, CP remains a clinical syndrome, but a molecular diagnosis can refine recurrence risk, prognosis, surveillance, and occasionally treatment. (fehlings2024comprehensivewholegenomesequence pages 26-28, fehlings2024comprehensivewholegenomesequence pages 17-19, lewis2024potentialclinicalapplications pages 1-2)

The following compact knowledge-base summary precedes the detailed report.

domain	high-confidence finding	quantitative data/example	ontology suggestions
Definition / IDs	Cerebral palsy (CP) is a group of permanent disorders of movement and posture due to a non-progressive disturbance/lesion of the developing fetal or infant brain; disease-level knowledge here is derived primarily from aggregated reviews, registries, and cohort studies rather than individual EHR alone. MONDO for cerebral palsy is available. (xu2024geneticpathwaysin pages 1-1, lewis2024potentialclinicalapplications pages 1-2, OpenTargets Search: cerebral palsy)	MONDO: `MONDO:0006497`; MeSH term present in ClinicalTrials browse: `D002547 Cerebral Palsy`.	MONDO:0006497; MeSH:D002547; HPO: HP:0100021 Cerebral palsy
Classification	Standard clinical subtype classification includes spastic, dyskinetic, ataxic, and hypotonic CP; function is commonly staged with GMFCS, MACS, CFCS, and EDACS. (xu2024geneticpathwaysin pages 2-3, novak2020stateofthe pages 4-6)	Slovenian pediatric cohort: spastic 85%, dyskinetic 13%, ataxic 2%. Functional systems: GMFCS I-V, MACS I-V. (silan2025unravellinggeneticetiology pages 1-2, novak2020stateofthe pages 4-6)	HPO: HP:0001257 Spasticity; HP:0001270 Motor delay; HP:0100022 Dyskinetic cerebral palsy; HP:0001251 Ataxia
Core phenotypes	CP is fundamentally a motor syndrome, often accompanied by cognitive, epilepsy, language, and mobility impairments; severity and participation limits vary widely. (xu2024geneticpathwaysin pages 1-1, xu2024geneticpathwaysin pages 2-3)	Approximate comorbidity frequencies from 2024 review: cognitive impairment ~50%, epilepsy ~33%, language impairment ~33%, ~40% unable to walk independently. (xu2024geneticpathwaysin pages 1-1)	HPO: HP:0001257 Spasticity; HP:0001263 Developmental regression not typical; HP:0001249 Intellectual disability; HP:0001250 Seizure; HP:0000750 Delayed speech and language development
Epidemiology	CP remains the most common childhood physical disability, with lower rates in many high-income settings than historically, but higher burden in low-/middle-income settings. (xu2024geneticpathwaysin pages 1-1, novak2020stateofthe pages 4-6, tegegne2023determinantsofcerebral pages 1-2)	Prevalence estimates: ~1.4-1.6 per 1,000 live births in some high-income settings; ~3.3-3.4 per 1,000 in LMIC settings; global range 1.5 to >4 per 1,000. Preterm infants account for ~43% of cases. (xu2024geneticpathwaysin pages 1-1, novak2020stateofthe pages 4-6, tegegne2023determinantsofcerebral pages 1-2)	MONDO:0006497; NCIT:C7639 Preterm Birth; HPO: HP:0001622 Premature birth
Etiology / risk factors	CP is etiologically heterogeneous: prematurity/low birth weight, low Apgar, intrauterine infection, congenital brain malformations, PROM, placental abruption, maternal disease, neonatal hyperbilirubinemia, stroke, and hypoxic-ischemic injury all contribute. (tegegne2023determinantsofcerebral pages 1-2, collins2024theimportanceof pages 1-2, xu2024geneticpathwaysin pages 2-3)	Systematic review found 40 consistent determinants from 95 articles; 24 studies implicated prematurity/low weight and 15 implicated low Apgar. HIE in term infants occurs in ~1.5/1,000 births and is a leading cause of CP. (tegegne2023determinantsofcerebral pages 1-2, collins2024theimportanceof pages 1-2)	HPO: HP:0001518 Small for gestational age; HP:0003819 Abnormality of the placenta; UBERON: placenta / brain; GO: GO:0006954 inflammatory response
Protective / preventive factors	Established prevention is mainly perinatal/neonatal: antenatal magnesium sulfate, antenatal corticosteroids, prophylactic caffeine in preterm infants, and therapeutic hypothermia for moderate-severe HIE. These are established care, not experimental. (novak2020stateofthe pages 4-6, klobucka2026evidenceandpractice pages 4-5)	Reported effect sizes/examples: magnesium sulfate prevents ~30% of CP in very preterm infants; therapeutic hypothermia prevents ~15% of hypoxia-associated cases when used within 6 hours. (novak2020stateofthe pages 4-6)	NCIT: magnesium sulfate, corticosteroid, caffeine, hypothermia; CHEBI: magnesium sulfate, caffeine
Genetic architecture	CP includes a substantial monogenic/CNV component and should not be treated as exclusively acquired. Recurrent genes/pathways converge on thrombosis, angiogenesis, mitochondrial/oxidative phosphorylation, neuronal migration, and autophagy, with overlap with broader neurodevelopmental disorders. (xu2024geneticpathwaysin pages 1-1, lewis2024potentialclinicalapplications pages 1-2)	Meta-analytic estimates cited in 2024 review: SNV molecular diagnostic yield ~23%, CNV yield ~5%. >100 recurrent genes discussed. (lewis2024potentialclinicalapplications pages 1-2)	HGNC gene examples: ATL1, CTNNB1, SPAST, PROC, COL4A1, L1CAM, KIF1A; GO: neuronal migration, oxidative phosphorylation, autophagy
2024 genomics development	Trio whole-genome sequencing has now provided large-scale direct evidence for CP genomic architecture. This is a key recent development. (fehlings2024comprehensivewholegenomesequence pages 26-28, fehlings2024comprehensivewholegenomesequence pages 17-19, fehlings2024comprehensivewholegenomesequence pages 21-24)	Nature Genetics 2024 cohort: 327 trios; pathogenic/likely pathogenic variants in 37/327 (11%), VUS in 58/327 (18%), no clinically relevant variant in 232/327 (71%); P/LP group had more cognitive impairment (49%) and brain maldevelopments (11%). (fehlings2024comprehensivewholegenomesequence pages 17-19, fehlings2024comprehensivewholegenomesequence pages 21-24)	HGNC: MT-TQ, MT-TS1, MT-ND5; GO: GO:0005739 mitochondrion; HPO: HP:0001250 Seizure; HP:0001249 Intellectual disability
Example implicated genes	Multiple cohorts identified plausible/definite CP-related variants, supporting clinical heterogeneity and genetic testing. (silan2025unravellinggeneticetiology pages 1-2, yigit2026unmaskinggeneticetiologies pages 1-2)	Slovenian cohort: 9/136 (6.6%) with ATL1, CTNNB1, DYRK1, KMT2A, PROC, SPAST, ZC4H2, ZSWIM6; 2026 integrative genomic cohort found P/LP variants in 24/66 (36.4%) with genes including SPAST, KIF1A, PLA2G6, CTNNB1, L1CAM, SYNGAP1. (silan2025unravellinggeneticetiology pages 1-2, yigit2026unmaskinggeneticetiologies pages 1-2)	HGNC: ATL1, CTNNB1, SPAST, KIF1A, PLA2G6, L1CAM, SYNGAP1
MRI / anatomy	Brain MRI is abnormal in most children with CP and helps classify etiology/anatomy; white matter injury is the most frequent MRI pattern, but normal MRI does not exclude CP or genetic causes. (lewis2024potentialclinicalapplications pages 1-2, silan2025unravellinggeneticetiology pages 1-2)	MRI categories (SCPE framework): maldevelopments, predominant white matter injury, predominant gray matter injury, miscellaneous abnormalities, normal. In one cited study: maldevelopments ~11%, white matter injury 49%, gray matter injury 21%; MRI abnormal in >80% overall. Normal MRI occurred in 42% of spastic diplegic CP in one series; 3/9 genetically solved Slovenian cases had normal MRI. (lewis2024potentialclinicalapplications pages 1-2, silan2025unravellinggeneticetiology pages 1-2)	UBERON: brain, cerebral white matter, cerebral cortex, basal ganglion, thalamus, cerebellum; HPO: HP:0002500 Abnormal cerebral white matter morphology
Pathophysiology / mechanism	A common mechanistic chain in acquired CP is prenatal/perinatal hypoxia-ischemia ± inflammation: reduced oxygen/blood flow causes primary energy failure, ATP depletion, lactate accumulation, ion pump failure, calcium overload, oxidative stress, necrosis/apoptosis, then secondary inflammatory injury affecting selective neurons and oligodendrocyte-lineage cells. (collins2024theimportanceof pages 1-2, koehler2018perinatalhypoxicischemicbrain pages 1-2)	HIE severe mortality cited at 25-50%; one-third to one-half of cooled survivors still had persistent neurologic abnormalities or low IQ at 6-7 years in large-animal review discussion. White matter injury and progenitor oligodendrocyte vulnerability are emphasized in fetal sheep and piglet models. (collins2024theimportanceof pages 1-2, koehler2018perinatalhypoxicischemicbrain pages 1-2)	GO: GO:0006091 generation of precursor metabolites and energy; GO:0006979 response to oxidative stress; GO:0006954 inflammatory response; CL: oligodendrocyte precursor cell, microglial cell, neuron
Diagnosis	Early diagnosis is increasingly feasible using clinical neurodevelopmental tools plus MRI; at-risk infants can often be identified far earlier than the historic 2-year diagnosis window. (klobucka2026evidenceandpractice pages 4-5, lewis2024potentialclinicalapplications pages 1-2)	Hammersmith Infant Neurological Examination + brain MRI allows reliable diagnosis in at-risk infants at ~5 months corrected age; reviews note prediction by 6-12 months and sometimes as early as 3 months corrected age with GMA/HINE/MRI. (klobucka2026evidenceandpractice pages 4-5, lewis2024potentialclinicalapplications pages 1-2)	NCIT: Magnetic Resonance Imaging; HPO: abnormal general movements; clinical tools: GMA, HINE, GMFCS
Differential / genomic workflow	Genetic evaluation is especially warranted when imaging/history are atypical or insufficient, including normal MRI, no clear perinatal insult, severe phenotype, family history, or CP-like/progressive presentations. This is increasingly recommended clinical workflow rather than purely research. (silan2025unravellinggeneticetiology pages 1-2, lewis2024potentialclinicalapplications pages 1-2)	2024 review: SNV yield ~23% and CNV yield ~5%; Slovenian cohort identified cases despite normal MRI or unremarkable history. Advanced genomic review argues for WES/WGS and other state-of-the-art genomic approaches to improve diagnosis. (lewis2024potentialclinicalapplications pages 1-2, silan2025unravellinggeneticetiology pages 1-2)	NCIT: Whole Exome Sequencing, Whole Genome Sequencing, Chromosomal Microarray Analysis
Established treatment: rehabilitation	Best-supported rehabilitation is early, active, task-specific, and goal-directed; technology can augment but not replace motor learning. NDT-Bobath is not superior to usual care. (novak2020stateofthe pages 13-14, klobucka2026evidenceandpractice pages 4-5, klobucka2026evidenceandpractice pages 12-13)	Traffic-light review covered 182 interventions and 398 outcomes; effective allied health examples include CIMT, bimanual training, treadmill/partial body-weight support training, strength training, goal-directed training, and home programs. (novak2020stateofthe pages 4-6, novak2020stateofthe pages 13-14)	NCIT: Physical Therapy, Occupational Therapy, Constraint-Induced Movement Therapy, Treadmill Training
Established treatment: pharmacologic / surgical	Established management for selected impairments includes botulinum toxin, intrathecal baclofen, selective dorsal rhizotomy, hip surveillance, scoliosis correction, and anticonvulsants, typically combined with rehabilitation. (novak2020stateofthe pages 13-14, klobucka2026evidenceandpractice pages 12-13)	Strong-evidence examples from systematic review: botulinum toxin, intrathecal baclofen, selective dorsal rhizotomy, anti-convulsants, dentistry, hip surveillance, scoliosis correction. (novak2020stateofthe pages 13-14)	NCIT: Botulinum Toxin, Baclofen, Selective Dorsal Rhizotomy, Hip Surveillance, Scoliosis Surgery
Unsupported / low-evidence care	Some commonly promoted interventions lack convincing benefit and should be distinguished from evidence-based care. (klobucka2026evidenceandpractice pages 12-13)	Examples flagged as lacking evidence in rehabilitation review: hyperbaric oxygen therapy, craniosacral manipulation, unstructured sensory integration, passive stretching without task-specific goals. (klobucka2026evidenceandpractice pages 12-13)	NCIT: Hyperbaric Oxygen Therapy; supportive note: low-evidence / not established
Prognosis	The brain lesion is non-progressive, but disability is lifelong and functional trajectories vary by subtype, GMFCS level, comorbidity burden, and response to therapy. Prognosis is influenced by prematurity, HIE severity, cognition, and associated impairments. (xu2024geneticpathwaysin pages 1-1, klobucka2026evidenceandpractice pages 4-5, collins2024theimportanceof pages 1-2)	Severe HIE mortality 25-50%; in a cohort of infants <25 weeks, males were more likely to develop CP and impaired cognition than females. Quality-of-life burden is substantial but precise modern disease-wide mortality/life expectancy estimates were not retrieved in this conversation. (collins2024theimportanceof pages 1-2)	HPO: HP:0001263 Global developmental delay; HP:0001249 Intellectual disability; ICF/GMFCS useful for prognosis
Current experimental / real-world trials	Ongoing interventional work includes neuromodulation, robotic exoskeleton gait therapy, biomarker-linked gait therapy, and stem-cell/conditioned-medium studies. These are experimental, not standard of care. (NCT06586437 chunk 1, NCT05158218 chunk 1, NCT04360395 chunk 1, NCT04314687 chunk 1)	Examples: NCT06586437 neuromodulation of cortex/spinal cord, randomized, double-masked, n=50; NCT05158218 robotic exoskeleton gait training vs physical therapy, randomized, n=64; NCT04360395 gait therapy with neurophysiology responder analysis, n=120; NCT04314687 allogeneic umbilical cord MSCs ± conditioned medium vs standard therapy, phase 1/2, n=78. (NCT06586437 chunk 1, NCT05158218 chunk 1, NCT04360395 chunk 1, NCT04314687 chunk 1)	NCIT: Transcutaneous Current Stimulation, Robotic Exoskeleton, Gait Therapy, Mesenchymal Stem Cell Therapy
Animal / translational models	CP has no single standard natural veterinary analogue; experimental models focus on hypoxia-ischemia, inflammation, hemorrhage, and prematurity-related injury. Large animals improve clinical translatability; rodent models remain useful mechanistically. (collins2024theimportanceof pages 1-2, koehler2018perinatalhypoxicischemicbrain pages 1-2)	Large-animal examples: fetal sheep for progenitor oligodendrocyte vulnerability and white matter injury; newborn piglets for term HIE systems injury; non-human primates for cortical/basal ganglia/thalamic injury patterns; maternal immune activation is an important added risk-factor model. Hypothermia success in human neonates was informed by animal work. (collins2024theimportanceof pages 1-2, koehler2018perinatalhypoxicischemicbrain pages 1-2)	NCBI Taxon examples: Mus musculus, Rattus norvegicus, Ovis aries, Sus scrofa, Macaca mulatta; GO/CL: oligodendrocyte precursor, microglia, neuron

Table: This compact table summarizes high-confidence, evidence-backed facts for a cerebral palsy knowledge-base entry, spanning definition, phenotypes, epidemiology, genetics, diagnosis, treatment, prognosis, and models. It distinguishes established care from experimental approaches and includes ontology suggestions for structured annotation.

1. Disease information

Definition and classification

The accepted construct is a group of permanent disorders of movement and posture causing activity limitation, attributable to non-progressive disturbances in the developing fetal or infant brain. “Permanent” describes the motor disorder; “non-progressive” describes the causal brain disturbance—not the person’s changing phenotype. CP may be spastic, dyskinetic, ataxic, hypotonic, or mixed and may be unilateral or bilateral. Function is classified separately with the five-level Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System (CFCS), and Eating and Drinking Ability Classification System (EDACS). (xu2024geneticpathwaysin pages 1-1, xu2024geneticpathwaysin pages 2-3)

Identifiers and synonyms

MONDO: MONDO:0006497.
MeSH: D002547, Cerebral Palsy.
ICD-10-CM: G80.-; important descendants include G80.0 spastic quadriplegic CP, G80.1 spastic diplegic CP, G80.2 spastic hemiplegic CP, G80.3 dyskinetic CP, G80.4 ataxic CP, G80.8 other CP, and G80.9 unspecified CP.
ICD-11: under cerebral palsy in developmental motor disorders; implementation-specific codes should be verified against the current national ICD-11 release.
OMIM/Orphanet: no single disease-wide Mendelian entry adequately represents CP because it is a descriptive syndrome; individual genetic CP/CP-mimic disorders have separate entries.
Synonyms: infantile cerebral palsy, cerebral palsies, static encephalopathy (the latter is broader and potentially misleading), spastic diplegia/hemiplegia/quadriplegia when subtype-specific.

Open Targets recognizes MONDO:0006497 and associates CP-related evidence with genes including SPAST, COL4A1, SNAP25, PMM2, and with AP-4-complex genes in spastic quadriplegic CP; these associations mix causal-disease and therapeutic-target evidence and therefore must not all be interpreted as disease-causing CP genes. (OpenTargets Search: cerebral palsy)

Data provenance: the report concerns aggregated disease-level evidence from cohorts, registries, trials, and reviews. Individual EHR observations can establish a patient’s phenotype but are not the source of the disease-level assertions here.

2. Etiology

CP is best represented as an endpoint reached through multiple causal routes.

Acquired and developmental factors

A 2023 systematic review identified 40 repeatedly reported determinants across 95 studies. Prematurity/low birth weight appeared in 24 studies and low Apgar score in 15. Other recurring factors were intrauterine infection, congenital brain malformation, premature rupture of membranes, placental abruption, maternal thyroid disease, fetal growth restriction, multiple gestation, neonatal CNS infection, stroke, and severe hyperbilirubinemia. Perinatal asphyxia was estimated to account for fewer than 10–20% of cases, emphasizing that temporal proximity to delivery does not prove intrapartum causation. (tegegne2023determinantsofcerebral pages 1-2)

Risk categories include:

Preconception/maternal: diabetes, epilepsy, thyroid disease, obesity, anemia, hypertension and pre-eclampsia; extremes of maternal age and assisted reproduction can mark increased risk but are not individually deterministic.
Placental/fetal: inflammation or infection, placental abruption/vascular malperfusion, congenital brain malformation, fetal growth restriction, multiple pregnancy, and fetal stroke.
Perinatal/neonatal: extreme prematurity, very low birth weight, intraventricular hemorrhage, periventricular white-matter injury, neonatal encephalopathy/HIE, sepsis/meningitis, severe jaundice/kernicterus, hypoglycemia, and cardiorespiratory instability.
Postneonatal: traumatic brain injury, CNS infection, stroke, drowning/hypoxia, and untreated status epilepticus during the early developmental period.

Genetic factors and gene-environment interaction

Genetic etiologies include de novo dominant variants, autosomal-recessive disorders, X-linked disorders, mitochondrial variants, and CNVs. A genetic lesion may cause maldevelopment directly, predispose to thrombosis or stroke (PROC, COL4A1/COL4A2), alter neuronal migration or axonal transport (CTNNB1, KIF1A, L1CAM, TUBA1A), or impair mitochondrial metabolism. Genetics may also modify vulnerability to environmental injury. Maternal inflammation can prime fetal microglia and amplify damage from a subsequent hypoxic-ischemic insult—the experimentally supported “two-hit” model. (xu2024geneticpathwaysin pages 1-1, collins2024theimportanceof pages 1-2, lewis2024potentialclinicalapplications pages 1-2)

Protective factors

No validated common protective human allele prevents CP. Established environmental/clinical protection is chiefly obstetric and neonatal: prevention of preterm birth and infection; antenatal corticosteroids when preterm delivery is expected; magnesium sulfate for fetal neuroprotection; caffeine in selected ventilated preterm infants; prompt resuscitation and treatment of jaundice, hypoglycemia and infection; and therapeutic hypothermia for eligible term/near-term infants with moderate-to-severe HIE. A major systematic review estimated approximately 30% prevention with antenatal magnesium sulfate in very-preterm populations and approximately 15% prevention of hypoxia-associated CP with timely hypothermia. (novak2020stateofthe pages 4-6)

3. Phenotypes

Motor manifestations begin in infancy or early childhood and vary from mild unilateral fine-motor impairment to profound four-limb and bulbar disability. The causal lesion is stable, but manifestations evolve with growth.

Spasticity—velocity-dependent hypertonia, hyperreflexia, clonus; severity variable. Suggested HPO: HP:0001257.
Motor-development delay—late head control, sitting, crawling or walking; infancy. HP:0001270.
Abnormal gait/toe walking/scissoring—primarily ambulant spastic CP. HP:0001288 (gait disturbance), HP:0002061 (lower-limb spasticity).
Dystonia/choreoathetosis—fluctuating postures and involuntary movement, especially dyskinetic CP. HP:0001332, HP:0002071.
Ataxia/tremor/dysmetria—usually childhood-recognized and non-degenerative. HP:0001251.
Unilateral weakness/asymmetry—hemiplegic CP, often after perinatal stroke. HP:0004374 or laterality-specific weakness terms.
Oromotor dysfunction, dysphagia, drooling—severity tracks motor impairment; affects nutrition, aspiration risk and participation. HP:0002015, HP:0002307.
Speech/language impairment—approximately one-third in a 2024 synthesis. HP:0000750, HP:0002465 (dysarthria). (xu2024geneticpathwaysin pages 1-1)
Intellectual/developmental impairment—approximately 50%; highly variable. HP:0001249, HP:0001263.
Epilepsy—approximately one-third; more frequent with cortical injury and severe bilateral CP. HP:0001250. (xu2024geneticpathwaysin pages 1-1)
Visual/hearing impairment, pain, sleep disorder, constipation, reflux, scoliosis, hip displacement, contractures and low bone density are important associated or secondary phenotypes.

In a relatively unselected Slovenian cohort, 85% had spastic, 13% dyskinetic and 2% ataxic CP; 36% were GMFCS I. (silan2025unravellinggeneticetiology pages 1-2)

Quality of life: pain, communication barriers, feeding dependence, fatigue, reduced mobility and inaccessible environments can restrict education, employment, relationships and community participation. Quality of life is not reducible to GMFCS: communication, pain, autonomy, family support and environmental inclusion are major modifiers. Disease-specific instruments include CP-QOL; generic tools include EQ-5D-Y, PedsQL, PROMIS and adult SF-36.

4. Genetic and molecular information

Architecture and implicated genes

CP has no single canonical causal gene. More than 100 recurrent genes have been reported, converging on axon guidance, synaptic function, vesicle transport, transcription, neuronal migration, thrombosis/angiogenesis, mitochondrial oxidative phosphorylation and autophagy. (xu2024geneticpathwaysin pages 1-1, lewis2024potentialclinicalapplications pages 1-2)

Examples include CTNNB1, SPAST, ATL1, KIF1A, L1CAM, AP4B1, AP4E1, AP4M1, AP4S1, COL4A1, COL4A2, PROC, GNAO1, KCNQ2, TUBB4A, TUBA1A, PDHA1, FAR1, PLA2G6, SYNGAP1, ZC4H2, ZSWIM6, and mitochondrial genes. These genes span dominant, recessive, X-linked and mitochondrial inheritance. They should be annotated to their specific molecular diagnoses rather than treated as interchangeable “CP genes.” (silan2025unravellinggeneticetiology pages 1-2, xu2024geneticpathwaysin pages 8-9, yigit2026unmaskinggeneticetiologies pages 1-2)

In the 2024 WGS study, 37/327 children (11%) had pathogenic/likely pathogenic variants and 58/327 (18%) had VUS. Cognitive impairment was more frequent in the P/LP group (49%) than in VUS (33%) or no-variant groups (22%; p=0.01). Mitochondrial variants included MT-TQ, MT-TS1, and MT-ND5. (fehlings2024comprehensivewholegenomesequence pages 17-19)

Variant interpretation

Reported pathogenic classes include loss-of-function nonsense, frameshift and splice variants; missense variants with loss-, gain-, or altered-channel function; CNVs; structural variants; and mitochondrial variants. Most severe monogenic findings are rare or absent from population databases. Allele frequency and ACMG/AMP classification must be recorded variant-by-variant from the current ClinVar and gnomAD release; no valid disease-wide allele frequency exists. VUS must not direct irreversible treatment or reproductive decisions without further evidence.

Modifiers, chromosomal and epigenetic findings

CNVs contribute an estimated ~5% diagnostic yield. Reported abnormalities include pathogenic deletions/duplications, but no single recurrent cytogenetic lesion defines CP. Epigenetic and methylation differences have been reported—including discordant monozygotic-twin studies—but causal direction and clinical utility remain unestablished. No validated modifier gene or methylation biomarker currently predicts severity in routine practice. (xu2024geneticpathwaysin pages 9-9, lewis2024potentialclinicalapplications pages 1-2)

5. Environmental information

Relevant exposures are principally developmental rather than adult lifestyle or occupational exposures. Maternal smoking, substance exposure, malnutrition, inadequate prenatal care, infection, obesity and socioeconomic disadvantage may alter risk through prematurity, fetal growth, placental function and access to care, but confounding is substantial. Environmental pollution and specific toxins are not established as direct common causes of CP.

Infectious contributors include maternal/fetal cytomegalovirus, toxoplasmosis, rubella, Zika virus and chorioamnionitis, and postnatal meningitis/encephalitis. Infection may cause direct neurotropism, malformation, vascular injury, or cytokine-mediated sensitization to hypoxia. Maternal or amniotic infection is a recognized risk factor for HIE, and maternal immune activation can produce persistent neuroimmune priming in models. (collins2024theimportanceof pages 1-2)

6. Mechanism and pathophysiology

Acquired-injury causal chain

Placental failure, infection, stroke or hypoxia-ischemia → reduced oxygen/glucose delivery → ATP depletion and anaerobic lactate accumulation → Na+/K+-pump failure and depolarization → glutamate excitotoxicity and intracellular Ca²⁺ accumulation → mitochondrial dysfunction, reactive oxygen species and protease activation → necrosis/apoptosis → secondary microglial/astrocytic inflammation → impaired oligodendrocyte maturation, myelination, axonal connectivity and neuronal circuit development → persistent motor-network dysfunction. Primary energy failure is upstream; delayed excitotoxic, oxidative and inflammatory injury is downstream and supplies a therapeutic window. (collins2024theimportanceof pages 1-2)

Preterm brains are especially vulnerable in cerebral white matter and pre-oligodendrocytes; term HIE more often injures deep gray nuclei, thalamus, perirolandic cortex, hippocampus or watershed cortex depending on insult pattern. Motor manifestations then arise from altered corticospinal, basal-ganglia-thalamocortical, cerebellar, sensory and spinal networks.

Genetic causal chains

Examples are COL4A1/PROC dysfunction → vascular fragility or thrombosis → fetal/perinatal stroke → unilateral spastic CP; tubulin/cytoskeletal defects → abnormal neuronal migration/axon formation → cortical malformation → motor impairment and epilepsy; and mitochondrial/pyruvate-metabolism defects → energy failure in vulnerable neurons → CP-like motor syndrome. Some genetic disorders are progressive and therefore CP mimics rather than CP itself.

Suggested GO processes: inflammatory response (GO:0006954), response to oxidative stress (GO:0006979), apoptotic process (GO:0006915), autophagy (GO:0006914), neuron migration (GO:0001764), axon guidance (GO:0007411), synaptic vesicle cycle (GO:0099504), myelination (GO:0042552), mitochondrial respiratory-chain complex assembly (GO:0033108), and angiogenesis (GO:0001525).

Cell Ontology suggestions: neuron (CL:0000540), cortical neuron, upper motor neuron, microglial cell (CL:0000129), astrocyte (CL:0000127), oligodendrocyte (CL:0000128), oligodendrocyte precursor cell, brain vascular endothelial cell and pericyte.

Molecular profiling and advanced technology

Transcriptomic, proteomic, metabolomic and methylomic studies report inflammatory, oxidative, lipid/myelin and energy-metabolism signatures, but none is a validated diagnostic test. The 2024 genomic review highlights long-read WGS, transcriptomics, epigenomics and improved structural/repeat-variant detection as routes for unresolved cases. Single-cell and spatial studies are mechanistically promising but not yet mature enough to define a universal CP cell atlas or clinical signature. (lewis2024potentialclinicalapplications pages 1-2)

7. Anatomical structures affected

The primary organ is the developing CNS. MRI patterns include maldevelopment, predominant white-matter injury, predominant gray-matter injury, miscellaneous lesions, or normal imaging. MRI is abnormal in more than 80% overall in cited series; one classification study attributed approximately 49% to white-matter injury, 21% to predominant gray-matter injury and 11% to maldevelopment. (lewis2024potentialclinicalapplications pages 1-2)

Suggested anatomical annotations include brain (UBERON:0000955), cerebral cortex, cerebral white matter, corticospinal tract, basal ganglion, thalamus, cerebellum, brainstem and spinal cord. Secondary structures include skeletal muscle, tendon, joint, hip, spine, bone, respiratory tract and gastrointestinal tract. Unilateral lesions commonly produce contralateral hemiplegia; bilateral white-matter lesions often produce diplegia; extensive bilateral cortex/deep-gray injury may produce quadriplegic or dyskinetic CP.

At the subcellular level, implicated compartments include mitochondria (GO:0005739), synapse (GO:0045202), axon (GO:0030424), myelin sheath (GO:0043209), cytoskeleton and lysosome/autophagosome.

8. Temporal development

The causal disturbance occurs prenatally, perinatally, or in early infancy while motor systems are developing. Clinical recognition is usually insidious: abnormal general movements, asymmetry, persistent primitive reflexes, abnormal tone or delayed milestones appear over months. GMA, HINE and MRI can predict CP by 3–6 months corrected age in high-risk infants, although historic diagnosis often occurred around age two in high-income and later in low-resource settings. (klobucka2026evidenceandpractice pages 4-5, lewis2024potentialclinicalapplications pages 1-2)

CP is chronic and lifelong without a conventional staging or remission system. GMFCS motor trajectories are more useful than “disease stages.” The lesion is static, but contracture, hip displacement, scoliosis, pain, fatigue and mobility decline can develop; learning, adaptation and therapy can improve activity and participation. Critical windows include fetal/neonatal neuroprotection and the first years of activity-dependent neuroplasticity.

9. Inheritance and population

Prevalence is generally about 1.5–2 per 1,000 live births globally, with reported ranges exceeding 4 per 1,000 and higher rates in resource-limited settings. A 2020 synthesis reported a ~30% decline in high-income settings to approximately 1.4/1,000, while Bangladesh remained approximately 3.4/1,000. Preterm infants accounted for 43% of cases. (novak2020stateofthe pages 4-6, tegegne2023determinantsofcerebral pages 1-2)

CP overall is multifactorial and does not have one inheritance pattern. Molecular subtypes can be autosomal dominant—often de novo—autosomal recessive, X-linked, mitochondrial, or CNV-mediated. Penetrance, expressivity, germline mosaicism, founder effects and carrier frequency must therefore be stated for the specific diagnosed disorder. Anticipation is not characteristic of CP as a syndrome. Consanguinity increases the probability of recessive CP-like disorders but is not a general cause.

Males are modestly overrepresented in many cohorts; the 2024 WGS cohort was 59.3% male. Biological vulnerability and differential survival may contribute. Socioeconomic and geographic gradients reflect prematurity, infection, neonatal care, ascertainment and rehabilitation access rather than ethnicity as an intrinsic cause. (fehlings2024comprehensivewholegenomesequence pages 21-24, collins2024theimportanceof pages 1-2)

10. Diagnostics

Clinical approach

Diagnosis is clinical: persistent disorder of movement/posture, activity limitation, onset during early development, and a non-progressive causal disturbance. Recommended assessment combines developmental history; neurologic examination; GMA in early infancy; HINE; standardized motor testing; hearing, vision, feeding, communication and cognitive assessment; and GMFCS/MACS/CFCS/EDACS classification. MRI is the principal etiologic imaging study. EEG is used for suspected seizures; EMG is reserved for specific neuromuscular differentials. There is no diagnostic blood test, biopsy or validated circulating biomarker.

Genomic workflow

A pragmatic workflow is: (1) verify phenotype and progression; (2) brain MRI and review pregnancy/perinatal history; (3) genetics referral and trio ES or GS, with CNV detection; (4) CMA if CNVs are not robustly assessed; (5) mtDNA testing, metabolic assays, repeat-expansion, RNA or long-read sequencing when phenotype indicates; (6) periodic reanalysis. Normal MRI, congenital anomalies, dysmorphism, family history, severe intellectual disability/epilepsy, no plausible acquired insult, or an unexpectedly progressive/fluctuating course increase diagnostic suspicion, but absence of these red flags does not exclude a genetic cause. Meta-analytic yields cited in 2024 were ~23% for SNVs and ~5% for CNVs. (silan2025unravellinggeneticetiology pages 1-2, lewis2024potentialclinicalapplications pages 1-2)

Differential diagnosis

Important mimics include hereditary spastic paraplegia (SPAST, ATL1, AP-4 genes), dopa-responsive dystonia, GNAO1 disorders, GLUT1 deficiency, mitochondrial disease, leukodystrophy, spinal muscular/neuromuscular disease, Rett-spectrum disease, neurodegeneration with brain iron accumulation, metabolic disorders and structural spinal disease. Regression, episodic decompensation, progressive weakness/spasticity, neuropathy, organ involvement or MRI evolution should prompt reconsideration.

There is no population newborn screen for CP. High-risk infant follow-up and standardized developmental surveillance constitute targeted early detection. Molecular cascade or reproductive testing applies only after a familial diagnosis.

11. Outcome and prognosis

Most individuals survive into adulthood, but survival varies markedly with gross-motor severity, feeding and respiratory impairment, epilepsy and intellectual disability. Severe HIE has reported mortality of 25–50%, but that statistic concerns the antecedent neonatal syndrome rather than all CP. Modern disease-wide five- and ten-year survival estimates were not available in the retrieved evidence and should not be inferred from HIE cohorts. (collins2024theimportanceof pages 1-2)

Ambulation, communication and self-care are strongly related to GMFCS/MACS/CFCS levels. Major morbidity includes pain, contracture, hip displacement, scoliosis, fractures, aspiration, malnutrition, constipation, epilepsy, sleep disorders and mental-health difficulties. Recovery of destroyed tissue is limited, but neuroplasticity, assistive technology, surgery and environmental accommodations can produce meaningful gains. Prognostic molecular biomarkers are not validated; MRI pattern, HINE, GMA, GMFCS, cognition, feeding safety and epilepsy currently carry greater clinical utility.

12. Treatment

There is no single disease-modifying cure. Management should be individualized, family-centered, goal-directed and multidisciplinary.

Established interventions

Rehabilitation: active, intensive, task-specific practice; goal-directed training; home programs; bimanual training; constraint-induced movement therapy; strength/fitness and treadmill training; mobility, communication, feeding, occupational and speech therapy. Passive, non-goal-directed treatment is less effective. (novak2020stateofthe pages 13-14, klobucka2026evidenceandpractice pages 4-5)
Spasticity/dystonia: oral baclofen, diazepam or selected alternatives; focal botulinum toxin A with active therapy/casting; intrathecal baclofen for selected generalized hypertonia. Drugs reduce symptoms but may cause weakness, sedation, dysphagia or systemic adverse effects.
Epilepsy/pain/bone and GI care: indication-specific antiseizure medication, analgesia, bisphosphonates in selected low-bone-density cases, nutrition and reflux/constipation management.
Surgery: selective dorsal rhizotomy for carefully selected spastic diplegia; orthopedic soft-tissue/bony procedures for contracture, hip displacement and gait; scoliosis correction; gastrostomy when safe nutrition cannot otherwise be maintained. Hip surveillance uses serial clinical examination and radiographic migration percentage. (klobucka2026evidenceandpractice pages 12-13)

Suggested NCIT intervention annotations include Physical Therapy, Occupational Therapy, Speech Therapy, Botulinum Toxin, Baclofen, Intrathecal Drug Administration, Selective Dorsal Rhizotomy, Orthopedic Surgery, Gastrostomy and Assistive Device.

No CP-specific CPIC pharmacogenomic algorithm is established. Genotype-guided treatment becomes relevant when testing reclassifies the phenotype—for example, a treatable neurotransmitter, transporter or metabolic disorder.

Experimental therapies and trials

Stem cells, conditioned medium, non-invasive neuromodulation, robotic devices and other regenerative approaches remain investigational. They should not be marketed as proven restoration.

NCT06586437: randomized, double-masked study of cortical/spinal transcutaneous current stimulation with imaging and neurophysiology; estimated n=50, active-not-recruiting. (NCT06586437 chunk 1)
NCT05158218: robotic exoskeleton gait training versus conventional gait therapy, 24 sessions over eight weeks; randomized, assessor-masked, n=64, active-not-recruiting. (NCT05158218 chunk 1)
NCT04360395: eight-week gait therapy with MEG/EEG, MRI and H-reflex characterization of responders; n=120, active-not-recruiting. (NCT04360395 chunk 1)
NCT04314687: phase 1/2 randomized trial of intrathecal allogeneic umbilical-cord mesenchymal stromal cells with or without conditioned medium versus physiotherapy; n=78, active-not-recruiting. (NCT04314687 chunk 1)

Hyperbaric oxygen, craniosacral manipulation, unstructured sensory integration and passive stretching without task goals lack convincing evidence. (klobucka2026evidenceandpractice pages 12-13)

13. Prevention

Primary prevention: optimize maternal health and vaccination; reduce smoking/substance exposure; prevent and treat maternal infection; prevent medically avoidable prematurity; use antenatal corticosteroids and magnesium sulfate when indicated; ensure safe obstetric and neonatal care. Magnesium sulfate and therapeutic hypothermia have the clearest CP-specific neuroprotective evidence. (novak2020stateofthe pages 4-6)

Secondary prevention: identify high-risk infants using neonatal history, MRI/ultrasound, GMA and HINE; initiate early active intervention before a delayed definitive label; promptly treat seizures, jaundice, hypoglycemia and infection.

Tertiary prevention: hip surveillance, nutrition/aspiration management, vaccination, epilepsy care, bone-health monitoring, contracture prevention, communication support and accessible participation. Genetic counseling should explain that recurrence may be low after a de novo variant, 25% for many recessive diagnoses, 50% for some dominant diagnoses, or follow maternal mitochondrial inheritance—but only after variant-specific interpretation.

14. Other species and natural disease

CP is a human clinical construct; there is no single established naturally occurring veterinary equivalent with a CP-specific breed ontology. Animals can naturally sustain congenital malformations, neonatal hypoxia, stroke or infection and show non-progressive motor impairment, but calling these cases “cerebral palsy” is generally analogical. There is no transmission or zoonotic potential.

Relevant taxa for comparative studies include mouse (Mus musculus, NCBI Taxon 10090), rat (Rattus norvegicus, 10116), rabbit (Oryctolagus cuniculus, 9986), sheep (Ovis aries, 9940), pig (Sus scrofa, 9823), and rhesus macaque (Macaca mulatta, 9544). Orthologs of causal human genes are studied in species-specific databases; their relevance depends on the molecular subtype.

15. Model organisms

Rodent Rice–Vannucci HI model: unilateral carotid ligation plus systemic hypoxia in neonatal mice/rats. Advantages are cost, genetic manipulation and molecular assays; limitations are unilateral, variably infarct-like injury and a small, lissencephalic, relatively white-matter-poor brain. (koehler2018perinatalhypoxicischemicbrain pages 1-2)
Perinatal rabbit HI: produces hypertonia, postural and locomotor abnormalities resembling CP; useful for motor-phenotype studies but less genetically tractable.
Fetal sheep: umbilical-cord occlusion or cerebral hypoperfusion; particularly useful for pre-oligodendrocyte vulnerability, white-matter injury and continuous fetal physiology.
Newborn piglet: gyrencephalic brain and human-like gray/white-matter organization; hypoxia/hypoperfusion reproduces term-HIE systems injury and permits intensive-care monitoring.
Non-human primate: partial asphyxia preferentially affects motor/somatosensory cortex, basal ganglia and thalamus, while complete asphyxia more strongly injures cerebellum, brainstem sensory nuclei and thalamus. Fidelity is high, but cost and ethical constraints are substantial. (koehler2018perinatalhypoxicischemicbrain pages 1-2)
Maternal-immune-activation plus HI models: capture gene/environment and infection/hypoxia “two-hit” biology. Model validity depends critically on inflammatory stimulus, dose, developmental timing and HI severity. (collins2024theimportanceof pages 1-2)
Genetic/cellular systems: knockout/knock-in animals, patient iPSC-derived neurons/glia, neural organoids and CRISPR-edited lines can test specific CP-associated variants, but cannot reproduce the full motor, placental and developmental context.

Animal work provided decisive translational support for neonatal hypothermia, illustrating the value of physiological large-animal models. No model reproduces the complete etiologic and phenotypic heterogeneity of human CP. (koehler2018perinatalhypoxicischemicbrain pages 1-2)

Key 2023–2024 sources and exact abstract statements

Fehlings et al., Nature Genetics, March 2024. “Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy.” DOI/URL: https://doi.org/10.1038/s41588-024-01686-x. This primary human trio-WGS study is the strongest recent genomic evidence retrieved. (fehlings2024comprehensivewholegenomesequence pages 26-28, fehlings2024comprehensivewholegenomesequence pages 17-19)
Lewis et al., eBioMedicine, August 2024. Exact summary: “Recent advancements in genomic technologies offer additional opportunities to uncover variations in human genomes, transcriptomes, and epigenomes that have previously escaped detection.” DOI/URL: https://doi.org/10.1016/j.ebiom.2024.105229. (lewis2024potentialclinicalapplications pages 1-2)
Xu et al., Neural Regeneration Research, September 2024. Exact abstract statement: “It is now widely acknowledged that genetic mutations and alterations play a pivotal role in cerebral palsy development, which can be further influenced by environmental factors.” DOI/URL: https://doi.org/10.4103/1673-5374.385855. (xu2024geneticpathwaysin pages 1-1)
Tegegne, Sudanese Journal of Paediatrics, 2023. Exact abstract statement: “The commonest determinants of CP in children are premature babies and low weight, low Apgar scores, intrauterine infection, congenital brain malformations, thyroid disease, premature rupture of membrane (PROM) and placental abruption.” DOI/URL: https://doi.org/10.24911/SJP.106-1670589241. (tegegne2023determinantsofcerebral pages 1-2)
Collins et al., Biomedicines, published 8 November 2024. Exact abstract statement: “The only proven therapy for HIE is therapeutic hypothermia.” DOI/URL: https://doi.org/10.3390/biomedicines12112559. (collins2024theimportanceof pages 1-2)

Evidence limitations

The strongest retrieved evidence supports definition, broad prevalence, genomic yield, MRI patterns, risk factors, neuroprotective interventions and selected rehabilitation approaches. Exact modern life-expectancy estimates, phenotype-specific quality-of-life effect sizes, validated CP-wide metabolomic/proteomic signatures, protective genetic alleles, and complete HGNC/OMIM/ClinVar variant-level mappings were not established in the retrieved corpus. Such fields should remain null or be populated only through a variant- or registry-specific curation rather than extrapolation.

References

(xu2024geneticpathwaysin pages 1-1): Yiran Xu, Yifei Li, Seidu A. Richard, Yanyan Sun, and Changlian Zhu. Genetic pathways in cerebral palsy: a review of the implications for precision diagnosis and understanding disease mechanisms. Neural Regeneration Research, 19:1499-1508, Sep 2024. URL: https://doi.org/10.4103/1673-5374.385855, doi:10.4103/1673-5374.385855. This article has 15 citations and is from a peer-reviewed journal.
(fehlings2024comprehensivewholegenomesequence pages 26-28): Darcy L. Fehlings, Mehdi Zarrei, Worrawat Engchuan, Neal Sondheimer, Bhooma Thiruvahindrapuram, Jeffrey R. MacDonald, Edward J. Higginbotham, Ritesh Thapa, Tarannum Behlim, Sabrina Aimola, Lauren Switzer, Pamela Ng, John Wei, Prakroothi S. Danthi, Giovanna Pellecchia, Sylvia Lamoureux, Karen Ho, Sergio L. Pereira, Jill de Rijke, Wilson W. L. Sung, Alireza Mowjoodi, Jennifer L. Howe, Thomas Nalpathamkalam, Roozbeh Manshaei, Siavash Ghaffari, Joseph Whitney, Rohan V. Patel, Omar Hamdan, Rulan Shaath, Brett Trost, Shannon Knights, Dawa Samdup, Anna McCormick, Carolyn Hunt, Adam Kirton, Anne Kawamura, Ronit Mesterman, Jan Willem Gorter, Nomazulu Dlamini, Daniele Merico, Murto Hilali, Kyle Hirschfeld, Kritika Grover, Nelson X. Bautista, Kara Han, Christian R. Marshall, Ryan K. C. Yuen, Padmaja Subbarao, Meghan B. Azad, Stuart E. Turvey, Piush Mandhane, Theo J. Moraes, Elinor Simons, George Maxwell, Michael Shevell, Gregory Costain, Jacques L. Michaud, Fadi F. Hamdan, Julie Gauthier, Kevin Uguen, Dimitri J. Stavropoulos, Richard F. Wintle, Maryam Oskoui, and Stephen W. Scherer. Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy. Nature genetics, 56:585-594, Mar 2024. URL: https://doi.org/10.1038/s41588-024-01686-x, doi:10.1038/s41588-024-01686-x. This article has 43 citations and is from a highest quality peer-reviewed journal.
(fehlings2024comprehensivewholegenomesequence pages 17-19): Darcy L. Fehlings, Mehdi Zarrei, Worrawat Engchuan, Neal Sondheimer, Bhooma Thiruvahindrapuram, Jeffrey R. MacDonald, Edward J. Higginbotham, Ritesh Thapa, Tarannum Behlim, Sabrina Aimola, Lauren Switzer, Pamela Ng, John Wei, Prakroothi S. Danthi, Giovanna Pellecchia, Sylvia Lamoureux, Karen Ho, Sergio L. Pereira, Jill de Rijke, Wilson W. L. Sung, Alireza Mowjoodi, Jennifer L. Howe, Thomas Nalpathamkalam, Roozbeh Manshaei, Siavash Ghaffari, Joseph Whitney, Rohan V. Patel, Omar Hamdan, Rulan Shaath, Brett Trost, Shannon Knights, Dawa Samdup, Anna McCormick, Carolyn Hunt, Adam Kirton, Anne Kawamura, Ronit Mesterman, Jan Willem Gorter, Nomazulu Dlamini, Daniele Merico, Murto Hilali, Kyle Hirschfeld, Kritika Grover, Nelson X. Bautista, Kara Han, Christian R. Marshall, Ryan K. C. Yuen, Padmaja Subbarao, Meghan B. Azad, Stuart E. Turvey, Piush Mandhane, Theo J. Moraes, Elinor Simons, George Maxwell, Michael Shevell, Gregory Costain, Jacques L. Michaud, Fadi F. Hamdan, Julie Gauthier, Kevin Uguen, Dimitri J. Stavropoulos, Richard F. Wintle, Maryam Oskoui, and Stephen W. Scherer. Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy. Nature genetics, 56:585-594, Mar 2024. URL: https://doi.org/10.1038/s41588-024-01686-x, doi:10.1038/s41588-024-01686-x. This article has 43 citations and is from a highest quality peer-reviewed journal.
(lewis2024potentialclinicalapplications pages 1-2): Sara A. Lewis, Andrew Ruttenberg, Tuğçe Iyiyol, Nahyun Kong, Sheng Chih Jin, and Michael C. Kruer. Potential clinical applications of advanced genomic analysis in cerebral palsy. Aug 2024. URL: https://doi.org/10.1016/j.ebiom.2024.105229, doi:10.1016/j.ebiom.2024.105229. This article has 5 citations and is from a peer-reviewed journal.
(OpenTargets Search: cerebral palsy): Open Targets Query (cerebral palsy, 34 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(xu2024geneticpathwaysin pages 2-3): Yiran Xu, Yifei Li, Seidu A. Richard, Yanyan Sun, and Changlian Zhu. Genetic pathways in cerebral palsy: a review of the implications for precision diagnosis and understanding disease mechanisms. Neural Regeneration Research, 19:1499-1508, Sep 2024. URL: https://doi.org/10.4103/1673-5374.385855, doi:10.4103/1673-5374.385855. This article has 15 citations and is from a peer-reviewed journal.
(novak2020stateofthe pages 4-6): Iona Novak, Catherine Morgan, Michael Fahey, Megan Finch-Edmondson, Claire Galea, Ashleigh Hines, Katherine Langdon, Maria Mc Namara, Madison CB Paton, Himanshu Popat, Benjamin Shore, Amanda Khamis, Emma Stanton, Olivia P Finemore, Alice Tricks, Anna te Velde, Leigha Dark, Natalie Morton, and Nadia Badawi. State of the evidence traffic lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Current Neurology and Neuroscience Reports, Feb 2020. URL: https://doi.org/10.1007/s11910-020-1022-z, doi:10.1007/s11910-020-1022-z. This article has 1632 citations and is from a domain leading peer-reviewed journal.
(silan2025unravellinggeneticetiology pages 1-2): Ula Arkar Silan, Ana Trebše, Jernej Kovač, Mihael Rogac, Anja Troha Gergeli, Robert Šket, Tina Bregant, David Neubauer, Borut Peterlin, and Damjan Osredkar. Unravelling genetic etiology of cerebral palsy: findings from a slovenian pediatric cohort. Frontiers in Neurology, Jul 2025. URL: https://doi.org/10.3389/fneur.2025.1615449, doi:10.3389/fneur.2025.1615449. This article has 1 citations and is from a peer-reviewed journal.
(tegegne2023determinantsofcerebral pages 1-2): Kaleab Tegegne. Determinants of cerebral palsy in children: systematic review. Sudanese journal of paediatrics, 23 2:126-144, Jan 2023. URL: https://doi.org/10.24911/sjp.106-1670589241, doi:10.24911/sjp.106-1670589241. This article has 13 citations.
(collins2024theimportanceof pages 1-2): Bailey Collins, Elise A. Lemanski, and Elizabeth Wright-Jin. The importance of including maternal immune activation in animal models of hypoxic–ischemic encephalopathy. Biomedicines, 12:2559, Nov 2024. URL: https://doi.org/10.3390/biomedicines12112559, doi:10.3390/biomedicines12112559. This article has 8 citations.
(klobucka2026evidenceandpractice pages 4-5): Stanislava Klobucká, Katarína Chamutyová, Robert Klobucký, Pavel Šiarnik, Ľudmila Podracká, and Branislav Kollár. Evidence and practice in the rehabilitation of patients with cerebral palsy: a structured narrative review informed by a systematic literature search. Bratislava Medical Journal, 127:1790-1812, Mar 2026. URL: https://doi.org/10.1007/s44411-026-00551-z, doi:10.1007/s44411-026-00551-z. This article has 2 citations.
(fehlings2024comprehensivewholegenomesequence pages 21-24): Darcy L. Fehlings, Mehdi Zarrei, Worrawat Engchuan, Neal Sondheimer, Bhooma Thiruvahindrapuram, Jeffrey R. MacDonald, Edward J. Higginbotham, Ritesh Thapa, Tarannum Behlim, Sabrina Aimola, Lauren Switzer, Pamela Ng, John Wei, Prakroothi S. Danthi, Giovanna Pellecchia, Sylvia Lamoureux, Karen Ho, Sergio L. Pereira, Jill de Rijke, Wilson W. L. Sung, Alireza Mowjoodi, Jennifer L. Howe, Thomas Nalpathamkalam, Roozbeh Manshaei, Siavash Ghaffari, Joseph Whitney, Rohan V. Patel, Omar Hamdan, Rulan Shaath, Brett Trost, Shannon Knights, Dawa Samdup, Anna McCormick, Carolyn Hunt, Adam Kirton, Anne Kawamura, Ronit Mesterman, Jan Willem Gorter, Nomazulu Dlamini, Daniele Merico, Murto Hilali, Kyle Hirschfeld, Kritika Grover, Nelson X. Bautista, Kara Han, Christian R. Marshall, Ryan K. C. Yuen, Padmaja Subbarao, Meghan B. Azad, Stuart E. Turvey, Piush Mandhane, Theo J. Moraes, Elinor Simons, George Maxwell, Michael Shevell, Gregory Costain, Jacques L. Michaud, Fadi F. Hamdan, Julie Gauthier, Kevin Uguen, Dimitri J. Stavropoulos, Richard F. Wintle, Maryam Oskoui, and Stephen W. Scherer. Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy. Nature genetics, 56:585-594, Mar 2024. URL: https://doi.org/10.1038/s41588-024-01686-x, doi:10.1038/s41588-024-01686-x. This article has 43 citations and is from a highest quality peer-reviewed journal.
(yigit2026unmaskinggeneticetiologies pages 1-2): Ayca Yigit, Ozlem Akgun-Dogan, Zeynep Ozkeserli, Gunseli Bayram Akcapınar, Semih Ayta, Pinar Gencpinar, Hulya Maras Genc, Busra Kutlubay, Bulent Kara, Hatice Gulhan Sozen, Nihat Bugra Agaoglu, Ozkan Ozdemir, Kaya Bilguvar, and Ugur Ozbek. Unmasking genetic etiologies in neurodevelopmental disorders characterized by cerebral palsy: insights from integrative genomic approaches. Frontiers in Neurology, Feb 2026. URL: https://doi.org/10.3389/fneur.2026.1742186, doi:10.3389/fneur.2026.1742186. This article has 0 citations and is from a peer-reviewed journal.
(koehler2018perinatalhypoxicischemicbrain pages 1-2): Raymond C Koehler, Zeng-Jin Yang, Jennifer K Lee, and Lee J Martin. Perinatal hypoxic-ischemic brain injury in large animal models: relevance to human neonatal encephalopathy. Journal of Cerebral Blood Flow & Metabolism, 38:2092-2111, Aug 2018. URL: https://doi.org/10.1177/0271678x18797328, doi:10.1177/0271678x18797328. This article has 109 citations and is from a highest quality peer-reviewed journal.
(novak2020stateofthe pages 13-14): Iona Novak, Catherine Morgan, Michael Fahey, Megan Finch-Edmondson, Claire Galea, Ashleigh Hines, Katherine Langdon, Maria Mc Namara, Madison CB Paton, Himanshu Popat, Benjamin Shore, Amanda Khamis, Emma Stanton, Olivia P Finemore, Alice Tricks, Anna te Velde, Leigha Dark, Natalie Morton, and Nadia Badawi. State of the evidence traffic lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Current Neurology and Neuroscience Reports, Feb 2020. URL: https://doi.org/10.1007/s11910-020-1022-z, doi:10.1007/s11910-020-1022-z. This article has 1632 citations and is from a domain leading peer-reviewed journal.
(klobucka2026evidenceandpractice pages 12-13): Stanislava Klobucká, Katarína Chamutyová, Robert Klobucký, Pavel Šiarnik, Ľudmila Podracká, and Branislav Kollár. Evidence and practice in the rehabilitation of patients with cerebral palsy: a structured narrative review informed by a systematic literature search. Bratislava Medical Journal, 127:1790-1812, Mar 2026. URL: https://doi.org/10.1007/s44411-026-00551-z, doi:10.1007/s44411-026-00551-z. This article has 2 citations.
(NCT06586437 chunk 1): Max Kurz. Neuromodulation of the Cortex and Spinal Cord. Father Flanagan's Boys' Home. 2024. ClinicalTrials.gov Identifier: NCT06586437
(NCT05158218 chunk 1): Max Kurz. Robotic Exoskeleton Gait Training in Adolescents With Cerebral Palsy. Father Flanagan's Boys' Home. 2021. ClinicalTrials.gov Identifier: NCT05158218
(NCT04360395 chunk 1): Max Kurz. Igniting Mobility in Adolescents and Young Adults With Cerebral Palsy. Father Flanagan's Boys' Home. 2020. ClinicalTrials.gov Identifier: NCT04360395
(NCT04314687 chunk 1): Stem Cell and Conditioned Medium for Cerebral Palsy. PT. Prodia Stem Cell Indonesia. 2021. ClinicalTrials.gov Identifier: NCT04314687
(xu2024geneticpathwaysin pages 8-9): Yiran Xu, Yifei Li, Seidu A. Richard, Yanyan Sun, and Changlian Zhu. Genetic pathways in cerebral palsy: a review of the implications for precision diagnosis and understanding disease mechanisms. Neural Regeneration Research, 19:1499-1508, Sep 2024. URL: https://doi.org/10.4103/1673-5374.385855, doi:10.4103/1673-5374.385855. This article has 15 citations and is from a peer-reviewed journal.
(xu2024geneticpathwaysin pages 9-9): Yiran Xu, Yifei Li, Seidu A. Richard, Yanyan Sun, and Changlian Zhu. Genetic pathways in cerebral palsy: a review of the implications for precision diagnosis and understanding disease mechanisms. Neural Regeneration Research, 19:1499-1508, Sep 2024. URL: https://doi.org/10.4103/1673-5374.385855, doi:10.4103/1673-5374.385855. This article has 15 citations and is from a peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.3.0.

Outcome	Count
References checked	11
Resolved	11
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	11
On topic	7
Off topic	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Diagnosis

Progression

Prevalence

Clinical Trials

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Cerebral Palsy: Disease-Characteristics Research Report

Executive summary

1. Disease information

Definition and classification

2. Etiology

Acquired and developmental factors

Genetic factors and gene-environment interaction

Protective factors

3. Phenotypes

4. Genetic and molecular information

Architecture and implicated genes

Variant interpretation

Modifiers, chromosomal and epigenetic findings

5. Environmental information

6. Mechanism and pathophysiology

Acquired-injury causal chain

Genetic causal chains

Molecular profiling and advanced technology

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical approach

Genomic workflow

Differential diagnosis

11. Outcome and prognosis

12. Treatment

Established interventions

Experimental therapies and trials

13. Prevention

14. Other species and natural disease

15. Model organisms

Key 2023–2024 sources and exact abstract statements

Evidence limitations

Artifacts

Reference Validation